The invention provides recombinant bacteria, which comprise a full complement of heterologous ethanol production genes. Expression of the full complement of heterologous ethanol production genes causes the recombinant bacteria to produce ethanol as the primary fermentation product when grown in mineral salts medium, without the addition of complex nutrients. Methods for producing the recombinant bacteria and methods for producing ethanol using the recombinant bacteria are also disclosed.
1. A recombinant bacterium which comprises a full complement of heterologous ethanol production genes. 2. The recombinant bacterium of 3. The recombinant bacterium of 4. The recombinant bacterium of 5. The recombinant bacterium of 6. The recombinant bacterium of 7. The recombinant bacterium of (a) the full complement of heterologous ethanol production genes that are integrated into a ribosomal RNA operon, wherein expression of said full complement of heterologous ethanol production genes causes the recombinant bacterium to produce ethanol as the primary fermentation product; and (b) one or more genes that encode polypeptides that facilitate production of ethanol or otherwise increase the amount of ethanol produced by the full complement of heterologous ethanol production genes; and wherein:
(i) one or more antibiotic markers are removed; and (ii) one or more genes encoding polypeptides that interfere with or otherwise reduce the amount of ethanol produced by the full complement of heterologous ethanol production genes are inactivated. 8. The recombinant bacterium of 9. The recombinant bacterium of 10. The recombinant bacterium of 11. The recombinant bacterium of 12. The recombinant bacterium of 13. The recombinant bacterium of 14. The recombinant bacterium of 15. The recombinant bacterium of 16. The recombinant bacterium of 17. The recombinant bacterium of any one of 18. The recombinant bacterium of 19. The recombinant bacterium of 20. The recombinant bacterium of 21. The recombinant bacterium of 22. The recombinant bacterium of 23. The recombinant bacterium of 24. The recombinant bacterium of 25. The recombinant bacterium of 26. The recombinant bacterium of 27. The recombinant bacterium of 28. The recombinant bacterium of 29. The recombinant bacterium of 30. The recombinant bacterium of 31. The recombinant bacterium of 32. The recombinant bacterium of 33. The recombinant bacterium of 34. The recombinant bacterium of 35. The recombinant bacterium of 36. The recombinant bacterium of 37. The recombinant bacterium of 38. The recombinant bacterium of 39. The recombinant bacterium of 40. The recombinant bacterium of 41. The recombinant bacterium of 42. The recombinant bacterium of 43. The recombinant bacterium of 44. The recombinant bacterium of 45. The recombinant bacterium of 46. The recombinant bacterium of 47. The recombinant bacterium of 48. The recombinant bacterium of 49. The recombinant bacterium of 50. The recombinant bacterium of 51. The recombinant bacterium of 52. The recombinant bacterium of 53. The recombinant bacterium of 54. The recombinant bacterium of 55. The recombinant bacterium of 56. A method for producing a recombinant bacterium of 57-111. (canceled) 112. A method for producing ethanol from an oligosaccharide source, comprising contacting the oligosaccharide with the recombinant bacterium of 113-125. (canceled) 126. A recombinant bacterium which comprises a full complement of heterologous ethanol production genes, wherein said recombinant bacterium is prepared by a process comprising the steps of the method of 127. (canceled) 128. A kit comprising the recombinant bacterium of 129. (canceled) 130. (canceled) 131. 132. 133.
This application claims the benefit of U.S. Ser. No. 60/836,726, filed Aug. 9, 2006, the entire contents of which is expressly incorporated herein by reference. Funding for the present invention was provided in part by the Government of the United States under Grant Nos.: 01-35504-10669 and 00-52104-9704 from the U.S. Department of Agriculture, and FG02-96ER20222 from the U.S. Department of Energy. The Government of the United States may have certain rights in and to the invention. Lignocellulosic biomass represents a renewable source of carbohydrate for biological conversion into fuels and chemicals and, as such, presents an attractive alternative to petroleum-based technology (Arntzen and Dale, 1999). It is recognized, however, that to reach its full potential, commodity production of ethanol from biomass will require high rates and efficiencies, simple processes, and inexpensive media (Ingram et al. 1998; Zhang & Greasham 1999). Bacteria such as To date, efforts to develop improved media and genetic modifications have been generally unsuccessful in eliminating the requirement for complex and costly nutrients, although betaine was found to be helpful (Underwood et al. 2004). Recently The present invention is based, at least in part, on the discovery of a new strategy for metabolic engineering of bacteria for ethanol production. In particular, the invention provides engineering strategies that overcome low ethanol yield and complex media requirements previously limiting to the engineering of bacteria for the production of ethanol in mineral salts medium. Prior art recombinant ethanologenic bacteria require complex nutrients to rapidly and efficiently produce high ethanol titers. Without being bound by theory, the inventors have identified four factors which can contribute to the limited performance of recombinant organisms such as KO11 in mineral salts media: (1) the arbitrary selection of pflB as the site of integration in KO11 of the The inventors have addressed these four factors. Consequently, the instant invention provides a recombinant bacterium, which is capable of growth and fermentation in mineral salts medium and which rapidly and efficiently produces ethanol in high titers. Accordingly, in one aspect, the invention provides a recombinant bacterium which comprises a full complement of heterologous ethanol production genes. In another aspect, the invention provides a recombinant bacterium which comprises a full complement of heterologous ethanol production genes, wherein the full complement of heterologous ethanol production genes is integrated into a ribosomal RNA operon. In a further aspect, the invention provides a recombinant bacterium which comprises a full complement of heterologous ethanol production genes, wherein one or more antibiotic markers are removed. In another further aspect, the invention provides a recombinant bacterium which comprises a full complement of heterologous ethanol production genes, wherein one or more genes encoding polypeptides that interfere with or otherwise reduce the amount of ethanol produced by the full complement of heterologous ethanol production genes are inactivated. In a further aspect, the invention provides a recombinant bacterium which comprises a full complement of heterologous ethanol production genes and one or more genes that encode polypeptides that facilitate production of ethanol or otherwise increase the amount of ethanol produced by the full complement of heterologous ethanol production genes. In an embodiment of each of the aforementioned aspects of the invention, expression of the full complement of heterologous ethanol production genes causes the recombinant bacterium to produce ethanol as the primary fermentation product. In one embodiment of the recombinant bacterium which comprises a full complement of heterologous ethanol production genes, the one or more genes are heterologous genes. In another aspect, the invention provides a recombinant bacterium which comprises a full complement of heterologous ethanol production genes that are integrated into a ribosomal RNA operon, wherein expression of the full complement of heterologous ethanol production genes causes the recombinant bacterium to produce ethanol as the primary fermentation product, and one or more genes that encode polypeptides that facilitate production of ethanol or otherwise increase the amount of ethanol produced by the full complement of heterologous ethanol production genes, and wherein the recombinant bacterium does not contain an antibiotic resistance marker, and one or more genes encoding polypeptides that interfere with or otherwise reduce the amount of ethanol produced by the full complement of heterologous ethanol production genes are inactivated. In certain embodiments, the ribosomal RNA operon comprises a gene selected from the group consisting of rrl A, rrlE, rrlC, FWD, rrlE, rrlG and rrlnH. In a particular embodiment, the ribosomal RNA operon comprises the rrlE gene. In another particular embodiment, the invention features the recombinant bacterium of any of the aspects of the invention, wherein the full complement of heterologous ethanol production genes comprises pdc, adhA and adhB. In a specific embodiment, the full complement of heterologous ethanol production genes is derived from In another embodiment, the recombinant bacterium has had an antibiotic resistance marker removed. In specific examples, the antibiotic resistance marker that is removed from the recombinant bacterium is selected from the group consisting of apramycin, kanamycin, tetracycline, ampicillin, and chloramphenicol. In one embodiment, one or more genes that are inactivated in the recombinant bacterium of the invention encode proteins involved in fermentative routes for NADH oxidation. In a particular embodiment, the one or more genes that are inactivated are endogenous to the bacterium. In another particular embodiment, the one or more genes that are inactivated are heterologous to the bacterium. In one embodiment of the invention, the one or more genes that are inactivated are selected from the group consisting of the genes comprising the focA-pflB gene region, ldhA, ackA, adhE, frd operon, casAB and mgsA. In a particular embodiment, the ackA, adhE, ldh genes and the frd operon encode proteins that are involved in alternate pathways for pyruvate metabolism. In one embodiment, the focA-pflB gene region, ldhA, ackA, adhE, genes comprising the frd operon and mgsA are endogenous genes. In another embodiment, the casAB genes are heterologous genes. In one embodiment, an ldhA gene is deleted. In another embodiment, the ldhA gene is an endogenous gene. In a further embodiment, the recombinant bacteria of the invention further comprise a focA-pflB gene region. In one embodiment, the focA-pflB gene region is an endogenous gene region. In another embodiment, the focA-pflB gene region is from The focA-pflB gene region was initially deleted to block the production of excess formate and acetyl-coA, which would reduce yield by consuming two NADH per ethanol using acetyl-coA as a substrate. In yet another embodiment of the invention, the gene that encodes a polypeptide that facilitates production of ethanol or otherwise increases the amount of ethanol produced by the full complement of heterologous ethanol production genes comprises an estZ gene. In one embodiment, the estZ gene is a heterologous gene. In another embodiment, the estZ gene is from The est gene helps to reduce the production of a very minor unwanted side product, ethyl acetate. Ethyl acetate separation from ethanol during final purification adds cost to the process. Yield changes are insignificant, but cost of purification can be significant. In another embodiment of the invention, the one or more genes that encode polypeptides that facilitate production of ethanol or otherwise increase the amount of ethanol produced by the full complement of heterologous ethanol production genes comprise lacA and lacY genes. In a particular embodiment, the lacA and lacY genes are endogenous genes. In another embodiment, the lacA and lacY genes are from In another embodiment of the invention, the one or more genes that encode polypeptides that facilitate production of ethanol or otherwise increase the amount of ethanol produced by the full complement of heterologous ethanol production genes comprise a celY gene. In a particular embodiment, the celY gene is a heterologous gene. In another particular embodiment, the celY gene is from In accordance with various aspects of the invention, the recombinant bacterium produces ethanol as the primary fermentation product under anaerobic conditions. The recombinant bacterium is also capable of growth in mineral salts medium. In a particular embodiment, the mineral salts medium contains xylose. In another embodiment, the medium comprises at least about 7% xylose. In still another embodiment, the medium contains betaine. In one embodiment, the ethanol produced by the recombinant bacterium comprises greater than 40% of total non-gaseous fermentation products under anaerobic conditions in mineral salts medium. In accordance with various aspects of the invention, the recombinant bacterium is derived from a bacterium that is Gram-positive or Gram-negative. In one embodiment, the bacterium is a Gram-negative bacterium selected from the group consisting of In another embodiment, the bacterium is a Gram-positive bacterium selected from the group consisting of In related aspects, the invention provides the following novel recombinant organisms: In other related aspects, the invention provides the recombinant Another aspect of the invention features a method for producing recombinant bacteria of the invention as described herein. The method comprises the step of integrating a full complement of heterologous ethanol production genes into a host bacterium, thereby producing a recombinant bacterium that comprises a full complement of heterologous ethanol production genes. In one embodiment, the method features integrating the full complement of heterologous ethanol production genes into a ribosomal RNA (rRNA) operon. In a particular embodiment, the RNA operon comprises a gene selected from the group consisting of rrl A, rrlE, rrlC, rrlD, rrlE, rrlG and rrlH. In still another particular embodiment, the ribosomal RNA operon comprises the rrlE gene. Another embodiment of the invention features recombinant bacterium as described herein, that does not contain an antibiotic resistance marker. In one embodiment, the methods further provide the step of removing one or more antibiotic markers. In yet another embodiment, the method features inactivating one or more genes encoding polypeptides that interfere with or otherwise reduce the amount of ethanol produced by the full complement of ethanol production genes. In still a further embodiment, the method features integrating one or more heterologous genes that encode polypeptides that facilitate production of ethanol or otherwise increase the amount of ethanol produced by the full complement of heterologous ethanol production genes. In another embodiment, the method further comprises the steps of integrating the full complement of heterologous ethanol production genes within the rrlE gene of the host bacterium, removing one or more antibiotic markers, and inactivating one or more genes encoding polypeptides that interfere with or otherwise reduce the amount of ethanol produced by the full complement of ethanol production genes not required for ethanol production. In a particular embodiment of the method, the full complement of heterologous ethanol production genes that is integrated comprises pdc, adhA and adhB. In a further embodiment of the method, the pdc, adhA and adhB genes are derived from In another embodiment of the method, the one or more genes are inactivated by deletion or mutation. In a particular embodiment, one or more ethanol production genes are inactivated by deletion. In another embodiment, genes encoding proteins involved in alternative routes of pyruvate metabolism are inactivated. In a further embodiment, the genes of any of the aspects of the invention are inactivated before the full complement of heterologous ethanol production genes is integrated. In one embodiment of the method, the host bacterium is In another embodiment of the method, genes comprising the focA-pflB gene region are inactivated by deletion. In another particular embodiment, the genes encoding proteins involved in alternate pathways for pyruvate metabolism are deleted. In one embodiment, the genes include ackA, adhE, ldhA and mgsA. In another embodiment, the endogenous ldhA gene is inactivated by deletion. In another embodiment, the ldhA gene is deleted before the full complement of heterologous ethanol production genes is integrated. In a further embodiment, the heterologous casAB genes are inactivated by deletion. In another embodiment, the casAB genes are from In one embodiment, the lac operon is removed or inactivated. In another embodiment of the method, the lac operon is restored. In a further embodiment, the genes restored from the lac operon comprise lacA, lacY and lacZ. In another embodiment, the genes comprising the lac operon are from In another embodiment of the method, the casAB genes are integrated. In a further embodiment, the casAB genes are integrated into the ldhA gene. In another embodiment, the casAB genes are from In another embodiment, the method further comprises restoring the function of the focA-pflB gene region. In a particular embodiment, the function of the focA-pflB gene region is restored by homologous recombination of the focA-pflB gene region. In another particular embodiment, the function of the focA-pflB gene region is restored before integration of the full complement of ethanol production genes. In one embodiment of the method, the host bacterium is In one embodiment of the foregoing methods of the invention, expression of the full complement of heterologous ethanol production genes causes the recombinant bacterium to produce ethanol as the primary fermentation product. Another aspect of the invention features a method for producing ethanol from an oligosaccharide source, comprising contacting the oligosaccharide with the recombinant bacterium of the invention as hereinabove described under conditions appropriate for ethanol production, thereby producing ethanol from an oligosaccharide source. In a particular embodiment of the method, the oligosaccharide is selected from the group consisting of lignocellulose, hemicellulose, cellulose, and pectin or a combination thereof. In another embodiment of the method, the ethanol produced comprises greater than 40% of total non-gaseous fermentation products. In one embodiment, the method further comprises providing the recombinant bacterium of the invention. In another embodiment, the invention further comprises obtaining the recombinant bacterium of the invention. Another embodiment of the invention further comprises contacting the oligosaccharide with the recombinant bacterium in mineral salts medium. In one embodiment, the mineral salts medium comprises per liter: 3.5 g KH2PO4, 5.0 g K2HPO4, 3.5 g (NH4)2HPO4, 0.25 g MgSO4.7H2O, 15 mg CaCl2.2H2O, 0.5 mg of thiamine, and 1 mL of trace metal stock, supplemented with 2 (w/v) % to 9 (w/v) % xylose. In another particular embodiment, betaine is added to the mineral salts medium. In another embodiment, MOPS is added to the mineral salts medium. In another embodiment, the mineral salts medium AM1 medium contains (per liter): 2.63 g (NH4)2HPO4, 0.87 g NH4H2PO4, 0.375 g/L MgSO4.7H2O, 0.149 g KCl, 0.0163 g Betaine HCl (pH 7.4), and 1.5 mL of trace metal stock, supplemented with 2 (w/v) % to 14 (w/v) % sugar. In a further embodiment, the AM1 medium contains xylose. In another embodiment, the AM1 medium comprises at least about 9% xylose. In still a further embodiment, trace metal stock can be prepared in 0.1M HCl (per liter: 1.6 g FeCl3.6H2O, 0.2 g CoCl2.6H2O, 0.1 g CuCl2.2H2O, 0.2 g ZnCl2, 0.2 g Na2MoO4.2H2O, 0.05 g H3BO3, 0.33 g MnCl2.4H2O). In one embodiment of the foregoing methods for producing ethanol from an oligosaccharide source, expression of the full complement of heterologous ethanol production genes causes the recombinant bacterium to produce ethanol as the primary fermentation product. A further aspect of the invention provides a recombinant bacterium which comprises a full complement of heterologous ethanol production genes, wherein the recombinant bacterium is prepared by a process comprising the steps of any one of the steps of the method of the invention as described hereinabove. In one embodiment, expression of the full complement of heterologous ethanol production genes causes the recombinant bacterium to produce ethanol as the primary fermentation product. Another aspect of the invention provides a kit comprising the recombinant bacterium of the invention as hereinabove described and instructions for use. In one embodiment, the instructions for use are in accordance with any of the methods of the invention for producing ethanol from an oligosaccharide source. In another embodiment, the kit further comprises a sugar source. In yet another embodiment, expression of the full complement of heterologous ethanol production genes causes the recombinant bacterium to produce ethanol as the primary fermentation product. In order for the full scope of the invention to be clearly understood, the following definitions are provided. The terms “host” and “host bacterium” are used interchangeably and are intended to include a bacterium, e.g., a naturally occurring bacterium or a recombinant bacterium, which serves as a host cell from which a recombinant bacterium of the invention is produced. Hence the recombinant bacterium of the invention is said to be “derived from” the host bacterium. The term “derived from” as in “polynucleotide or gene derived from a bacterium” is intended to include the isolation (in whole or in part) of a polynucleotide segment from the indicated source (i.e., the bacterium) or the purification of a polypeptide from an indicated source (i.e., the bacterium). In this regard, the term is intended to include, for example, direct cloning, PCR amplification, or artificial synthesis from, or based on, a sequence associated with the indicated polynucleotide source. As used herein the terms “recombinant bacterium,” “recombinant host cell,” “recombinant microorganism,” and the like, are intended to include cells suitable for, or subjected to, genetic manipulation, or to incorporate heterologous polynucleotide sequences by transfection. The cell can be a microorganism or a higher eukaryotic cell. The term is intended to include progeny of the host cell originally transfected. In some embodiments, the host cell is a bacterial cell, e.g., a Gram-positive bacterial cell or a Gram-negative bacterial cell. Gram-positive bacterial host cells include, e.g., A “gene,” as used herein, is a nucleic acid that can direct synthesis of an enzyme or other polypeptide molecule, e.g., can comprise coding sequences, for example, a contiguous open reading frame (ORF) that encodes a polypeptide, or can itself be functional in the organism. A gene in an organism can be clustered in an operon, as defined herein, wherein the operon is separated from other genes and/or operons by intergenic DNA. Individual genes contained within an operon can overlap without intergenic DNA between the individual genes. In addition, the term “gene” is intended to include a specific gene for a selected purpose. A gene can be endogenous to the host cell or can be recombinantly introduced into the host cell, e.g., as a plasmid maintained episomally or a plasmid (or fragment thereof) that is stably integrated into the genome. A heterologous gene is a gene that is introduced into a cell and is not native to the cell. In accordance with the invention, a heterologous gene also includes an endogenous gene that is introduced into the cell at a location other than its natural location in the genome of the cell. The term “heterologous ethanol production gene” is intended to include a gene or portion thereof that is derived from any source, e.g., eukaryotes, prokaryotes, archaea, virii, or synthetic nucleic acid fragments, that encodes a polypeptide involved in the production of ethanol as a primary fermentation production, and that is incorporated into a host cell to which the gene is not native. The term “heterologous ethanol fermentation gene” also refers to a gene that encodes a polypeptide involved in the fermentation of a carbohydrate, for example in a metabolic pathway of an organism that produces ethanol as the primary fermentation produced by an organism, that is not naturally occurring in an organism, e.g., a gene that is introduced into the organism. The terms “heterologous ethanol production gene” and “heterologous ethanol fermentation gene” may be used interchangeably and are intended to include a gene that is involved in at least one step in the bioconversion of a carbohydrate to ethanol. Accordingly, the term is intended to include any gene encoding a polypeptide such as an alcohol dehydrogenase, a pyruvate decarboxylase, a secretory protein/s, or a polysaccharase e.g., a glucanase, such as an endoglucanase or exoglucanase, a cellobiohydrolase, β-glucosidase, endo-1, 4-β-xylanase, β-xylosidase, α-glucuronidase, α-L-arabinofuranosidase, acetylesterase, acetylxylanesterase, α-amylase, β-amylase, glucoamylase, pullulanase, β-glucanase, hemicellulase, arabinosidase, mannanase, pectin hydrolase, or pectate lyase. The phrase “full complement of heterologous ethanol production genes” is meant to include substantially all the genes that have evolved in an ethanologenic organism, from which the heterologous ethanol production genes are obtained/derived, that comprise the organism's natural ethanol production pathway. A full complement of ethanol production genes includes substantially all the genes of an ethanologenic organism that direct fermentation away from metabolic pathways involving enzymes that do not produce ethanol as the primary fermentation product (“alternate metabolic pathways”). Such alternate metabolic pathways include alternate pathways for pyruvate metabolism and fermentative pathways for NADH oxidation. For example, the full complement of heterologous ethanol production genes of The phrase “alternate pathways for pyruvate metabolism” is intended to include a subset of fermentative pathways for NADH oxidation. The phrase is meant to include metabolic pathways involving enzymes that do not produce ethanol as the primary fermentation product. One example of such alternate pathways includes those pathways that produce lactate and succinate as the primary fermentation products. Other examples of such pathways are wasteful pathways. A wasteful pathway oxidizes two NADH molecules per ethanol, rather than one per ethanol, as in the preferred pathway of the instant invention, and thus reduces the final yield. Examples of wasteful alternate pathways for pyruvate metabolism include pathways involving enzymes such as alcohol dehydrogenase E (adhE) and acetate kinase (ackA). A further example of an alternate pathway for pyruvate metabolism includes the pathway encoded by the ldhA (lactate dehydrogenase) gene. LdhA encodes a one-enzyme pathway for the metabolism of NADH+ pyruvate to produce NAD+ and lactate. Yet another example of an alternate pathway for pyruvate metabolism includes pathways involving the genes that encode the four subunits of the fumarate reductase complex (the FRD operon) in addition to NADH and pyruvate that together oxidize NADH to NAD+ where the end product from pyruvate is succinate. The term alternative pathways for pyruvate metabolism, in certain embodiments, encompasses a subset of fermentative pathways for NADH oxidation. The term “ribosomal RNA operon” is intended to mean the cluster of ribosomal RNA genes that are expressed as a group and their associated promoter and operator. There are seven ribosomal RNA (rRNA) operons, called rrlA, rrlB, rrlC, rrlD, rrlE, rrlG, and rrlH (Lindhal et al. 1986; Nomura et al., 1984). By convention, the term “rrlE” refers to one set of genes encoding all three ribosomal RNAs whereas the term “RRLE” refers to an rrlE gene product, i.e., a 23S, 16S, 5S rrlE ribosomal RNA molecule. An rrlE equivalent is present in most if not all organisms. An exemplary rrlE sequence is specified by GeneID number 948509. Each rRNA operon contains a 16S rRNA gene, a 23S rRNA gene, and a 5S rRNA gene, interspersed with various tRNA genes. The rrlD operon contains two 5S rRNA genes. “rrs” genes encode 16S rRNAs, “rrl” genes encode 23S rRNAs, and “rrf” genes encode 5S rRNAs. The terms “inactivated” or “inactivate” are intended to include any means by which a gene is stopped from encoding its intended polypeptide or from encoding an active form of its intended polypeptide. Accordingly, the terms include, for example, mutation, deletion, insertion, duplication, missense, frameshift, repeat, nonsense mutation, or other alteration or modification such that gene activity (i.e. transcription) is blocked. For example, in accordance with one embodiment of the invention, one or more genes encoding polypeptides that interfere with or otherwise reduce the amount of ethanol produced by the full complement of heterologous ethanol production genes are inactivated by deletion. The term “pyruvate decarboxylase” (pdc) is intended to include the enzyme that serves to direct the flow of pyruvate into ethanol during fermentation. By convention, the term “pdc” refers to a pyruvate decarboxylase gene whereas the term “PDC” refers to a pdc gene product, i.e., a pyruvate decarboxylase polypeptide or enzyme. An exemplary pdc sequence is the The terms “alcohol dehydrogenase A” (adhA) and “alcohol dehydrogenase B” (adhB) and “alcohol dehydrogenase E” (adhE) are intended to include the enzymes that convert acetaldehyde to ethanol under fermentative conditions. By convention, the term “adhA,” “adhB” or “adhE” refers to an alcohol dehydrogenase gene whereas the term “ADHA,” “ADHB” or “ADHE” refers to an “adhA,” “adhB” or “adhE” gene product, respectively, i.e., an alcohol dehydrogenase polypeptide or enzyme. An exemplary adhA sequence is the The term “focA-pflB gene region” (focA-pflB gene region) is intended to include the focA, pflB genes involved in pyruvate metabolism. The term “pyruvate formate lyase” (pflB) is intended to include the enzyme that converts pyruvate to Acetyl-CoA and formate under fermentative conditions. By convention, the term “pflB” refers to a pyruvate formate lyase gene whereas the term “PFL” refers to a pfl gene product, i.e., a pyruvate formate lyase polypeptide or enzyme. An exemplary pflB sequence is the The term “lactate dehydrogenase” (ldhA) is intended to include the enzyme that converts pyruvate to lactate under fermentative conditions. By convention, the term “ldhA” refers to a lactate dehydrogenase gene whereas the term “LDHA” refers to an ldhA gene product, a lactate dehydrogenase polypeptide or enzyme. An exemplary ldhA sequence is the The term “acetate kinase” (ackA) is intended to include the enzyme that encodes an alternative route for pyruvate metabolism. By convention, the term “ackA” refers to an acetate kinase gene whereas the term “ACKA” refers to an ackA gene product, i.e., an acetate kinase polypeptide or enzyme. An exemplary ackA sequence is the The term “frd operon” is intended to include the four subunits that comprise the fumarate reductase complex (A-D). By convention, the term “frd operon” refers to the genes which encode the four subunits, whereas the term “FRD OPERON” refers to the proteins which encode the four subunits. An exemplary fumarate reductase A sequence is the The term “cas AB” (casAB) is intended to include the enzymes Enzyme II cellobiose and phospho-beta-glucosidase that ferment cellubiose. By convention, the term “casAB” refers to the casAB genes whereas the term “CASAB” refers to the casAB gene product, i.e., a casAB enzyme. Exemplary casA and casB sequences are the The term “celY” (celY) is intended to include the enzyme endoglucanase Y. By convention, the term “celY” refers to the celY gene whereas the term “CELY” refers to the celY gene product, i.e., a celY enzyme. An exemplary celY sequence is the The term “methylglyoxal synthaseA” (mgsA) is intended to include the enzyme that encodes the enzyme mgsA in the first step of the methylglyoxal bypass pathway. By convention, the term “mgsA” refers to a methylglyoxal synthase gene whereas the term “MGSA” refers to an mgsA gene product, i.e., a methylglyoxal synthaseA polypeptide or enzyme. An exemplary mgs sequence is the The term “short chain esterase” (estZ) is intended to include the enzyme that encodes a short chain esterase from The term “lac operon” is intended to include one regulatory gene (the i gene) and three structural genes (z, y, and a). By convention, the term “lac operon” refers to the genes, whereas the term “LAC OPERON” refers to the proteins which encode the four genes. The i gene codes for the repressor of the lac operon. The z gene codes for beta-galactosidase, the y gene codes for permease, and the a gene encodes a transacetylase. The term “lacA” (lacA) is intended to include galactose transacetylase, an enzyme involved in lactose metabolism. By convention, the term “lacA” refers to a galactose transacetylase gene whereas the term “LACA” refers to a lacA gene product, i.e., a galactose transacetylase polypeptide or enzyme. An exemplary lacA sequence is the The term “lacY” (lacY) is intended to include permease, an enzyme involved in lactose metabolism. By convention, the term “lacY” refers to a permease gene whereas the term “LACY” refers to a lac Y gene product, i.e., a permease polypeptide or enzyme. An exemplary lacY sequence is the The term “chloramphenicol transacetylase” (cat) is intended to include the enzyme that causes antibiotic resistance to chloramphenicol. By convention, the term “cat” refers to a chloramphenicol transacetylase gene whereas the term “CAT” refers to a cat gene product, i.e., a chloramphenicol transacetylase polypeptide or enzyme. An exemplary cat sequence is the The terms “fermentation” and “fermenting” are intended to include the degradation or depolymerization of a complex sugar and bioconversion of that sugar residue into ethanol, lactate, acetate and succinate under anaerobic condition. The terms are intended to include the enzymatic process (e.g. cellular or acellular, e.g. a lysate or purified polypeptide mixture) by which ethanol is produced from a carbohydrate, in particular, as a primary product of fermentation. The term “mineral salts medium” is intended to include a medium that contains a minimal amount of nutrients, e.g., one that consists essentially of mineral salts and other fundamental nutrients, but that enables a recombinant organism, e.g., a recombinant bacterium, of the invention to grow under anaerobic conditions and produce ethanol as the primary fermentation product without the need to add complex nutrients. For example, the novel The term “Gram-negative bacteria” is intended to include the art-recognized definition of this term. Exemplary Gram-negative bacteria include The term “Gram-positive bacteria” is intended to include the art-recognized definition of this term. Exemplary Gram-positive bacteria include The term “ethanologenic” is intended to include cells that have the ability to produce ethanol from a carbohydrate as a primary fermentation product. The term is intended to include naturally occurring ethanologenic organisms, ethanologenic organisms with naturally occurring or induced mutations, and recombinant organism genetically engineered to produce ethanol from a carbohydrate as a primary fermentation product. The term “non-ethanologenic” is intended to include cells that are unable to produce ethanol from a carbohydrate as a primary non-gaseous fermentation product; i.e., cells that produce ethanol as a minor fermentation product. The term “primary fermentation product” is intended to include non-gaseous products of fermentation (e.g., ethanol) that comprise greater than about 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of total non-gaseous product. The primary fermentation product is the most abundant non-gaseous product. In certain embodiments of the invention, the primary fermentation product is ethanol. In further embodiments, the primary fermentation products are produced by the host grown in mineral salts medium. The term “minor fermentation product” as used herein is intended to include non-gaseous products of fermentation (e.g., ethanol) that comprise less than 40%, for example 20%, 30%, 40%, of total non-gaseous product. The term “anaerobic conditions” in intended to include conditions in which there is significantly less oxygen than is present in an aerobic environment. In particular embodiments, there is 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% less oxygen in the anaerobic environment than in the aerobic environment. The term “simultaneous saccharification and fermentation” or “SSF” is intended to include the use of one or more recombinant hosts (or extracts thereof, including purified or unpurified extracts) for the contemporaneous degradation or depolymerization of a complex sugar and bioconversion of that sugar residue into ethanol by fermentation. SSF is a well-known process that can be used for breakdown of biomass to polysaccharides that are ultimately convertible to ethanol by bacteria. Reflecting the breakdown of biomass as it occurs in nature, SFF combines the activities of fungi (or enzymes such as cellulases extracted from fungi) with the activities of ethanologenic bacteria (or enzymes derived therefrom) to break down sugar sources such as lignocellulose to simple sugars capable of ultimate conversion to ethanol. SSF reactions are typically carried out at acid pH to optimize the use of the expensive fungal enzymes. The term “homologous recombination” refers to the crossing over of DNA that occurs between two homologous DNA molecules. According to the invention, homologous recombination can occur between genes to restore gene function, i.e. homologous recombination to restore pflB function. In another embodiment, homologous recombination can be used to remove an antibiotic resistance marker. The terms “saccharide,” “saccharide source,” “oligosaccharide source,” “oligosaccharide,” “complex cellulose,” “complex carbohydrate,” “complex sugar,” “polysaccharide,” “sugar source,” “source of a fermentable sugar” and the like are intended to include any carbohydrate source comprising more than one sugar molecule. Sugars include glucose, xylose, arabinose, mannose, galactose, sucrose, and lactose. The term “saccharide,” as used herein, also includes, e.g., disaccharides, trisaccharides, oligosaccharides, and polysaccharides. These carbohydrates may be derived from any unprocessed plant material or any processed plant material. Examples are wood, paper, pulp, plant derived fiber, or synthetic fiber comprising more than one linked carbohydrate moiety, i.e., one sugar residue. One particular saccharide source is “lignocellulose,” which represents approximately 90% of the dry weight of most plant material and contains carbohydrates, e.g., cellulose, hemicellulose, pectin, and aromatic polymers, e.g., lignin. Cellulose makes up 30%-50% of the dry weight of lignocellulose and is a homopolymer of cellobiose (a dimer of glucose). Similarly, hemicellulose makes up 20%-50% of the dry weight of lignocellulose and is a complex polymer containing a mixture of pentose (xylose, arabinose) and hexose (glucose, mannose, galactose) sugars which contain acetyl and glucuronyl side chains. Pectin makes up 1%-20% of the dry weight of lignocellulose and is a methylated homopolymer of glucuronic acid. Other saccharide sources include carboxymethyl cellulose (CMC), amorphous cellulose (e.g., acid-swollen cellulose), and the cellooligosaccharides cellobiose, cellotriose, cellotetraose, and cellopentaose. Cellulose, e.g., amorphous cellulose may be derived from a paper or pulp source (including, e.g., fluid wastes thereof) or, e.g., agricultural byproducts such as corn stalks, soybean solubles, or beet pulp. Any one or a combination of the above carbohydrate polymers is a potential source of sugars for depolymerization and subsequent bioconversion to ethanol by fermentation according to the products and methods of the present invention. The term “obtaining” as in “obtaining the recombinant bacterium” is intended to include purchasing, preparing, engineering or otherwise acquiring the recombinant bacterium. The term “providing” as in “providing the recombinant bacterium” is intended to include selling, distributing or otherwise making available the recombinant bacterium. “ATCC” followed by a number appearing in parentheses following an organism name refers to a deposit of the organism made with the American Type Culture Collection, 10801 University Blvd. Manassas, Va. 20110-2209. “NRRL” followed by a number appearing in parentheses following an organism name refers to a deposit of the organism made with the National Center for Agricultural Utilization Research, 1815 North University Street, Peoria, Ill. 61604-3999. As discussed, the invention provides new and recombinant cells, in particular recombinant bacteria, suitable for degrading sugars. The cells have improved ethanol production capabilities, particularly in mineral salts medium. The cells comprise a full complement of heterologous ethanol production genes. Expression of the full complement of heterologous ethanol production genes causes the recombinant cells to produce ethanol as the primary fermentation product. The invention also provides a host cell that serves as the basis for the development of a recombinant cell that is genetically engineered to comprise a full complement of heterologous ethanol production genes. Accordingly, the host cell can be a cell of a higher eukaryotic organism such as a nematode, an insect, a reptile, a bird, an amphibian, or a mammal. The cell can also be a cell of a single-celled or multi-cellular microorganism, such as a fungus, yeast, or bacterium. The recombinant host cells and recombinant cells derived therefrom are intended to include cells suitable for, or subjected to, genetic manipulation, or to incorporate heterologous polynucleotide sequences by transfection. Recombinant host cells include progeny of the host cell originally transfected. Accordingly, suitable host cells in accordance with the invention include yeast cells such as, e.g., The host cell can be a non-recombinant or recombinant bacterial host cell. In certain embodiments, bacterial host cells in accordance with the invention include Gram-positive bacteria, e.g., As discussed, the invention provides recombinant cells, in particular recombinant bacteria, comprising a full complement of heterologous ethanol production genes. The recombinant bacteria of the invention are able to produced ethanol as the primary fermentation product when grown in mineral salts medium. A full complement of heterologous ethanol production genes includes substantially all the genes that have evolved in an ethanologenic organism from which the genes are derived that comprise the organism's natural ethanol production pathway. Included within the scope of the invention are heterologous ethanol production genes derived from yeast and Gram-positive or Gram-negative bacteria. Thus, suitable heterologous polynucleotide sequences for use in constructing recombinant organisms in accordance with the invention are derived from, e.g., adh and/or pdc genes from naturally occurring ethanologenic organisms, such as One or more of the ethanol production genes comprising the full complement can be derived from different organisms or from the same organisms. In advantageous embodiments, the genes comprising the full complement are derived from the same organism. In one embodiment of the invention, the genes comprising the full complement of heterologous ethanol production genes are pdc, adhA and adhB. In an advantageous embodiment, the pdc, adhA and adhB genes are from Included within the scope of the present invention are heterologous ethanol production genes or gene products which differ from naturally-occurring ethanol production genes, for example, genes which have nucleic acids that are mutated, inserted or deleted, but which encode polypeptides substantially similar and functionally equivalent to the naturally-occurring gene products of the present invention, e.g., a mutant polypeptide having pyruvate decarboxylase activity that serves to direct the flow of pyruvate into ethanol during fermentation. For example, it is well understood to one of skill in the art that nucleic acids which code for conservative amino acid substitutions can be mutated (e.g., by substitution). It is further well understood to one of skill in the art that amino acids in the naturally occurring gene products can be substituted, added or deleted to a certain degree without substantially affecting the function of a gene product (e.g., without affecting the biological function of pyruvate decarboxylase as an enzyme that serves to direct the flow of pyruvate into ethanol during fermentation) as compared with a naturally-occurring gene product. These well understood principles are included within the scope of the present invention. Thus, although in some embodiments, the full complement of heterologous ethanol production genes can comprise, for example, the naturally occurring pdc, adhA and adhB genes of In particular aspects of the invention, the full complement of heterologous ethanol production genes is integrated into a ribosomal RNA operon of the host cell. A ribosomal RNA operon is shared by most if not all cells, particularly microorganisms, particularly bacteria. As noted above, there are seven ribosomal RNA (rRNA) operons, called rrlA, rrnlE, rrlC, rrlD, rrlE, rrlG, and rrlH (Lindhal et al. 1986; Nomura et al., 1984). By convention, the term “rrnlE” refers to the rrnlE gene encoding the ribosomal RNAs (23S, 16S and 5S) whereas the term “RRLE” refers to a rrnlE gene product, i.e., a ribosomal RNA polypeptide. An rrnlE equivalent is present in most if not all organisms. An exemplary rrnlE sequence is specified by GeneID number 9485094. Each rRNA operon contains a 16S rRNA gene, a 23S rRNA gene, and a 5S rRNA gene, interspersed with various tRNA genes. The rrnD operon contains two 5S rRNA genes. “rrs” genes encode 16S rRNAs, “rrl” genes encode 23S rRNAs, and “rrf” genes encode 5S rRNAs. In advantageous embodiments, the RNA operon comprises a gene selected from the group consisting of rrl A, rrlB, rrlC, rrlD, rrlE, rrlG and rrlH. In other aspects, the invention provides a recombinant bacterium which comprises a full complement of heterologous ethanol production genes as herein before described, wherein one or more antibiotic markers are removed. In general, genes encoding antibiotic markers are used in recombinant engineering techniques to identify or mark the presence of a particular genotype/phenotype. In certain embodiments, recombinant organisms of the invention which produce ethanol as the primary fermentation product can be inhibited by the presence of antibiotic markers. Therefore, such antibiotic markers are advantageously removed from the recombinant organisms. In some embodiments, antibiotic markers targeted for removal include, e.g., those selected from the group consisting of apramycin, kanamycin, tetracycline, ampicillin and chloramphenicol. In certain embodiments, apramycin and kanamycin markers are removed. In still other aspects, the invention provides a recombinant bacterium which comprises a full complement of heterologous ethanol production genes as hereinbefore described, wherein one or more genes encoding polypeptides that interfere with or otherwise reduce the amount of ethanol produced by the full complement of heterologous ethanol production genes are inactivated. In accordance with the invention, any gene present in the host cell whose transcription interferes with or otherwise reduces the amount of ethanol produced by the full complement of heterologous ethanol production genes can be targeted for inactivation. Genes that can be targeted for inactivation include but are not limited to genes comprising the focA-pflB gene region, ldhA, ackA, adhE, frd operon, casAB and mgsA. Thus, in certain embodiments, genes encoding polypeptides involved in all fermentative routes for NADH oxidation are inactivated. In particular embodiments, genes encoding polypeptides that are involved in alternate pathways for pyruvate metabolism are inactivated. Such genes include, for example, ackA and adhE. Together AckA and AdhE form a wasteful pathway for ethanol production that can, in certain embodiments, be eliminated as a wasteful route for use of NADH. LDHA eliminated oxidation of NADH by concurrent production-reduction of pyruvate to lactate. In an advantageous embodiment, a msgA gene is inactivated by deletion. This gene encodes a protein involved in the Methylglyoxal Bypass, a spillover pathway which is a potential source of lactate in In certain embodiments, the genes are endogenous to the host cell. Endogenous genes include, but are not limited to, ldhA, ackA, adhE, genes comprising the frd operon, genes comprising the focA-pflB gene region and mgsA. In other embodiments, the genes are heterologous to the host cell. Heterologous genes include, but are not limited to, casAB. In other aspects, the invention provides a recombinant bacterium which comprises a full complement of heterologous ethanol production genes as hereinbefore described, and which further comprises one or more genes that encode polypeptides that facilitate production of ethanol or otherwise increase the amount of ethanol produced by the full complement of heterologous ethanol production genes. Such genes can be endogenous or heterologous and are integrated into the host cell by any number of techniques well known to those of skill in the art. In another aspect, the invention provides a recombinant bacterium which comprises a full complement of heterologous ethanol production genes as hereinbefore described, and where the recombinant bacterium is prepared by a process comprising the steps of the method as described in any of the aspects of the invention. Any gene which encodes a polypeptide that facilitates production of ethanol or otherwise increases the amount of ethanol produced by the full complement of heterologous ethanol production genes can be targeted for integration into the host cell. Such genes include, e.g., those that encode a secretory protein/s, a polysaccharase e.g., a glucanase, such as an endoglucanase or exoglucanase, a cellobiohydrolase, β-glucosidase, endo-1, 4-β-xylanase, β-xylosidase, α-glucuronidase, α-L-arabinofuranosidase, acetylesterase, acetylxylanesterase, α-amylase, β-amylase, glucoamylase, pullulanase, β-glucanase, hemicellulase, arabinosidase, mannanase, pectin hydrolase, and pectate lyase. A naturally occurring gene or a gene derived from the naturally occurring gene can be integrated. Thus, this aspect of the invention encompasses genes or gene products which differ from naturally-occurring genes and includes, for example, genes which have nucleic acids that are mutated, inserted or deleted, but which encode polypeptides substantially similar and functionally equivalent to the naturally-occurring gene products. In certain embodiments, the gene, for example the est gene of In other embodiments, the genes, for example the lacA and lacY genes of The recombinant organisms provided by the invention are characterized by their ability to produce ethanol as the primary fermentation product. They are further characterized by their ability to produce ethanol as the primary fermentation product when grown in mineral salts medium. As discussed, the recombinant organisms of the invention comprise a full complement of heterologous ethanol production genes and, therefore, are ethanologenic. By ethanologenic is meant that the ethanol produced comprises greater than 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of total non-gaseous product. The primary fermentation product is the most abundant non-gaseous product produced under anaerobic conditions, in particular when grown in mineral salts medium. Exemplary recombinant organisms in accordance with the invention are novel Recombinant bacteria in accordance with the invention, e.g., The present invention provides methods of making the recombinant organisms having the aforementioned attributes. Accordingly, in another aspect, the invention provides a method for producing a recombinant bacterium that comprises a full complement of heterologous ethanol production genes, wherein the expression of the full complement of heterologous ethanol production genes causes the recombinant bacterium to produce ethanol as the primary fermentation product. The method comprises the step of integrating the full complement of heterologous ethanol production genes into a host bacterium, thereby producing a recombinant bacterium that produces ethanol as the primary fermentation product. Methods of making recombinant ethanologenic microorganisms are known in the art of molecular biology. Suitable materials and methods and recombinant host organisms are described, for example, in U.S. Pat. Nos. 7,026,152, 6,849,434, 6,333,181, 5,821,093; 5,482,846; 5,424,202; 5,028,539; 5,000,000; 5,487,989, 5,554,520, and 5,162,516 and in WO2003/025117 hereby incorporated by reference, and may be employed in carrying out the present invention. The bacterium of the invention comprises a full complement of heterologous ethanol production genes. The full complement of genes includes a nucleic acid molecule (e.g., a DNA molecule or segment thereof), for example, a polypeptide or RNA-encoding nucleic acid molecule that, in an organism, is separated from another gene or other genes, by intergenic DNA (i.e., intervening or spacer DNA which naturally flanks the gene and/or separates genes in the chromosomal DNA of the organism). A gene can direct synthesis of an enzyme or other polypeptide molecule (e.g., can comprise coding sequences, for example, a contiguous open reading frame (ORE) which encodes a polypeptide) or can itself be functional in the organism. A gene in an organism can be clustered in an operon, as defined herein, wherein the operon is separated from other genes and/or operons by intergenic DNA. Individual genes contained within an operon can overlap without intergenic DNA between the individual genes. Also included in the scope of the invention are promoterless operons, which are operons lacking the promoter portion (e.g., an frd operon). An isolated gene as described herein, includes a gene which is essentially free of sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived (i.e., is free of adjacent coding sequences which encode a second or distinct polypeptide or RNA molecule, adjacent structural sequences or the like) and optionally includes 5′ and 3′ regulatory sequences, for example promoter sequences and/or terminator sequences. An isolated gene includes predominantly coding sequences for a polypeptide (e.g., sequences which encode PDC polypeptides). As mentioned above, the full complement of heterologous ethanol producing genes is incorporated into a host cell. In certain embodiments, the host cell is a bacterium and is also referred to as “the parent strain”. In some embodiments, the parent strain is a non-recombinant bacterium. For example, the parent strain can be a naturally occurring non-ethanologenic bacterium, e.g., In other embodiments of the invention, the parent strain can be a recombinant organism. In such embodiments, the parent strain can contain both wild-type and heterologous genes encoding polypeptides that reduce the amount of ethanol produced by the strain, for example, when grown in mineral salts medium. Wild-type genes include genes that are present in the parent strain. Heterologous genes include exogenous genes that have been added to the parent strain. Exemplary host cells for use in the methods according to the invention include, e.g., The invention also encompasses various embodiments of the method for making the recombinant organisms described herein. Thus, in one embodiment, the method further comprises integrating the full complement of heterologous ethanol production genes into a ribosomal RNA operon. In an advantageous embodiment, the ribosomal RNA operon comprises a gene selected from the group consisting of rrl A, rrlE, rrnC, rrlD, rrlE, rrlG and rrlnH. In another advantageous embodiment, the ribosomal RNA operon comprises rrlE. In yet another embodiment, the method further comprises removing one or more antibiotic markers. In one embodiment, the antibiotic markers are selected from the group consisting of apramycin, kanamycin, tetracycline, ampicillin and chloramphenicol. In a particular embodiment, the antibiotic markers are apramycin and kanamycin. The antibiotic marker can be removed by inactivating (e.g., by deletion) the gene coding for the marker by any of a number of methods known in the art. In an advantageous embodiment, the gene(s) encoding the antibiotic marker(s), e.g., kanamycin and apramycin, is removed by homologous recombination, using a recombinase. In yet another embodiment, the method further comprises inactivating one or more genes encoding polypeptides that interfere with or otherwise reduce the amount of ethanol produced by the full complement of ethanol production genes. In accordance with the invention, such genes are inactivated by any of a number of means, well known to those of skill in the art, by which a gene is stopped from encoding its intended polypeptide or from encoding an active form of its intended polypeptide. Accordingly, such genes are inactivated by, for example, mutation, deletion, insertion, duplication, missense, frameshift, repeat, nonsense mutation, or other alteration or modification such that gene activity (i.e., transcription) is blocked or transcription results in functionally inactive polypeptides. In accordance with advantageous embodiments of the invention, genes are inactivated by deletion. In a further embodiment, the method further comprises integrating one or more heterologous genes that encode polypeptides that facilitate production of ethanol or otherwise increase the amount of ethanol produced by the full complement of heterologous ethanol production genes. The very same methods described above that are used to integrate the full complement of ethanol production genes can be used to integrate genes that encode polypeptides that facilitate production of ethanol or otherwise increase the amount of ethanol produced by the full complement of heterologous ethanol production genes. One of ordinary skill in the art will recognize that based on the aforementioned examples, and based on homology among bacterial strains, the methods of the instant invention are not limited to the strains taught in the instant application. The recombinant bacteria of the invention produce ethanol from an oligosaccharide source. Accordingly, the invention provides a method for producing ethanol from an oligosaccharide source comprising contacting said oligosaccharide with a recombinant bacterium of the invention under conditions appropriate for ethanol production, thereby producing ethanol from an oligosaccharide source. In one embodiment, the oligosaccharide and the recombinant bacterium are contacted in mineral salts medium, optionally containing betaine. In a particularly advantageous embodiment, the recombinant bacteria grow in mineral salts medium and produce ethanol as the primary fermentation product in high titers. In accordance with the methods of the invention, the recombinant bacteria described herein degrade or depolymerize a complex saccharide into a monosaccharide. Subsequently, the recombinant bacteria, by virtue of the full complement of heterologous ethanol production genes they carry, catabolize the simpler sugar into ethanol by fermentation. This process of concurrent complex saccharide depolymerization into smaller sugar residues followed by fermentation is referred to as simultaneous saccharification and fermentation (SSF). Typically, fermentation conditions are selected that provide an optimal pH and temperature for promoting the best growth kinetics of the producer host cell strain and catalytic conditions for the enzymes produced by the culture (Doran et al., (1993) Currently, the conversion of a complex saccharide such as lignocellulose is a very involved, multi-step process. For example, the lignocellulose must first be degraded or depolymerized using acid hydrolysis. This is followed by steps that separate liquids from solids and these products are subsequently washed and detoxified to result in cellulose that can be further depolymerized and finally, fermented by a suitable ethanologenic host cell. In contrast, the fermenting of corn is much simpler in that amylases can be used to break down the corn starch for immediate bioconversion by an ethanologenic host in essentially a one-step process. Accordingly, it will be appreciated by the skilled artisan that the recombinant hosts and methods of the invention afford the use of a similarly simpler and more efficient process for fermenting lignocellulose. For example, the method of the invention is intended to encompass a method that avoids acid hydrolysis altogether. Moreover, the hosts of the invention have the following advantages, 1) efficiency of pentose and hexose co-fermentation; 2) resistance to toxins; 3) production of enzymes for simultaneous saccharification and fermentation; and 4) environmental hardiness. Therefore, the complexity of depolymerizing lignocellulose can be simplified using an improved biocatalyst of the invention. Indeed, in one preferred embodiment of the invention, the reaction can be conducted in a single reaction vessel and in the absence of acid hydrolysis, e.g., as an SSF process. One advantage of the invention is the ability to use a saccharide source that has been, heretofore, underutilized. Consequently, a number of complex saccharide substrates may be used as a starting source for depolymerization and subsequent fermentation using the recombinant bacteria and methods of the invention. Ideally, a recyclable resource may be used in the SSF process. Mixed waste office paper is a preferred substrate (Brooks et al., (1995) As noted above, the recombinant organisms provided by the invention produce ethanol as the primary fermentation product, in particular when grown in mineral salts medium. In mineral salts medium, the novel recombinant The invention is further illustrated by the following examples, which should not be construed as limiting. The following materials and methods were used throughout the Examples below. 1. Organisms and Culture Conditions Strains and Plasmids: Table 1, below, lists the organisms and plasmids used to construct the recombinant microorganisms of the invention. Re-engineered ethanologenic strains were grown in NBS mineral salts medium (Causey et al., 2003) containing per liter: 3.5 g KH2PO4, 5.0 g K2HPO4, 3.5 g (NH4)2HPO4, 0.25 g MgSO4.7H20, 15 mg CaCl2.2H2O, 0.5 mg of thiamine, and 1 mL of trace metal stock, supplemented with 2 (w/v) % to 9 (w/v) % xylose. Trace metal stock can be prepared in 0.1M HCl (per liter: 1.6 g FeCl3, 0.2 g CoCl2.6H2O, 0.1 g CuCl2, 0.2 g ZnCl2.4H2O, 0.2 g NaMoO4, 0.05 g H3BO3). Betaine (1 mM) and MOPS (4-Morpholinepropanesulfonic acid) buffer (100 mM, pH 7.4) were added where indicated, as described (Underwood et al. 2004). After LY168 was developed a more economical mineral salts medium, AM1 medium, was used (Martinez et al., 2007) containing per liter: 2.63 g (NH4)2HPO4, 0.87 g NH4H2PO4, 0.375 g/L MgSO4.7H2O, 0.149 g KCl, 0.0163 g Betaine HCl (pH 7.4), and 1.5 mL of trace metal stock, supplemented with 2 (w/v) % to 14 (w/v) % sugar, as indicated. Trace metal stock can be prepared in 0.1M HCl (per liter: 1.6 g FeCl3.6H2O, 0.2 g CoCl2.6H2O, 0.1 g CuCl2.2H2O, 0.2 g ZnCl2, 0.2 g Na2MoO4.2H2O, 0.05 g H3BO3, 0.33 g MnCl2.4H2O). Ethanologenic strains were screened on aldehyde indicator plates for alcohol dehydrogenase activity as previously described (Conway et al. 1987). Esterase activity was examined using the methyl red assay described previously (Hasona et al. 2002). Cellobiose utilization was evaluated using MacConkey agar with 2% cellobiose. Endoglucanase activity was evaluated on CMC agar plates (Wood et al., 1997). 2. Genetic Methods Unless otherwise described, standard methods were used for plasmid construction, transformation, electroporation, conjugation, and PCR amplification (Miller, 1992; Sambrook & Russell 2001). cat-sacB Procedure In the first recombination using the cat-sacB cassette, part of the target gene was replaced by a DNA cassette containing a chloramphenicol resistance gene (cat) and levansucrase gene (sacB). In the second recombination, the cat-sacB cassette was removed by selection for resistance to sucrose, followed by testing for sensitivity to chloramphenicol. Cells containing the sacB gene accumulate levan during incubation with sucrose and are killed. Surviving recombinants are highly enriched for loss of the cat-sacB cassette. A new cassette was constructed as a template to facilitate gene deletions. The cat-sacB region was originally amplified from pEL04 (Lee et al., 2001; Thomason et al., 2005) by PCR using the primer pair JMcatsacBNheI (Table 2), digested with NheI, and modified and ligated into a modified pUC19 vector with Pad sites flanking the inserted cassette, creating pLOI4162. The cat-sacB cassette can be digested with Pad, and used in subsequent ligations The primers used in the methods described are listed in Table 2, below. Taq PCR Master Mix (QIAGEN, Inc., Valencia, Calif.) was used to construct deletions and for analyses. Platinum Pfx DNA polymerase (Invitrogen, Carlsbad, Calif.) and Easy-A High-Fidelity PCR Cloning Enzyme (Stratagene, La Jolla, Calif.) were used to amplify functional genes for chromosomal integration. Integration of linearized DNA was facilitated by using plasmid pKD46 (Datsenko & Wanner 2000). FRT-flanked antibiotic genes were used for selection to facilitate subsequent removal with recombinase (Martinez-Morales et al. 1999; Posfai et al. 1997). Chromosomal constructions were verified by PCR analyses and phenotype. In certain embodiments of the invention, antibiotic markers, e.g. antibiotic gene markers, can be removed by homologous recombination. Homologous recombination is carried out using a using recombinase that introduces site-specific breaks into the target DNA, for example a flp recombinase. 3. Fermentation Fermentation tests were carried out in 500 mL fermentation vessels with automatic pH control (37° C., pH 6.5, and 150 rpm; 350 ml working volume) as described by Underwood et al. 2004, using NBS mineral salts medium (9% xylose, and 1 mM betaine where indicated) or AM1 medium in 95 or 14% xylose where indicated. Pre-inocula were grown at 37° C. for 24-48 h in NBS mineral medium containing 9.0 (w/v) % xylose and 1 mM betaine in standing screw capped tubes, and transferred to small fermentors. After incubation for 24 h, broth was used to inoculate for test fermentations (10-16 mg dcw l−1inoculum). In some cases, small fermentations were sequentially transferred after 24 h or 48 h to co-select improved growth and ethanol production. No antibiotics were added to broth for seed or fermentation tests. 4. Analytical Methods Cell mass was estimated from the optical density at 550 nm with a Bausch & Lomb Spectronic™ 70 spectrophotometer. Ethanol was measured by gas chromatography (Ohta et al. 1991). Organic acids were determined by HPLC as described (Causey et al. 2003). The Referring to The LY149 strain lacks all major routes for anaerobic NADH oxidation and is incapable of fermentative growth on sugars even in rich medium. Since the deletions of adhE and ackA in LY149 make a deletion of pflB unnecessary, this region was restored by homologous recombination using a 9 kb fragment from pLOI3901 ( To construct this plasmid, the pflB region (ycaO-ycaN) was amplified as 2 PCR fragments and assembled into pLOI3495 in three pieces: 1) HindIII to SfcI (Klenow) fragment (ycaN′-ycaK; 764 bp) ligated into unique EcoRV and HindIII sites; 2) Klenow-treated SfcI fragment (pflA-pflB′; 2,084 bp) ligated into the Klenow-treated SpeI site); and 3) AscI to NotI fragment (pfl′-ycaO; 4,657 bp) ligated into corresponding sites of pLOI3495. In pLOI3901, an FRT-flanked aac gene for selection is located between ycaK and pflA. Function of pflB was restored in strain LY149 by homologous recombination using the NotI to HindIII fragment (ycaO-focA-pflB-pflA-FRT-aac-FRT-rrnBT1 terminator-ycaK-ycaN′) with selection for apramycin resistance. The resulting strain was designated LY151; this strain produced formate, indicative of pyruvate formate lyase (pflB) activity. In previous studies, a mineral set of genes from Plasmid pLOI3491 was constructed by ligating the The donor strain, S17-1λpir, is unable to grow in mineral salts medium due to an auxotrophic requirement for proline. The recipient strain, LY151, is unable to grow fermentatively due to the lack of a pathway for NADH oxidation. Together, these provided a unique opportunity for direct functional selection without antibiotics. Since ATP production by glycolysis and growth are obligately coupled to functional expression of a fermentation pathway, selection for growth in NBS mineral salts medium was used to co-select optimal strains (site of insertion, expression level) for ethanol production from a library of random LY151 exconjugants harboring the ethanol production cassette. S17-1λpir (pLOI3491) and LY151 were mated on LB plates (2% glucose). Pooled exconjugants were inoculated into 1-liter bottles, filled to the brim with NBS mineral salts medium (5% xylose, 100 mM MOPS, pH 7.4) and incubated at 37° C. (150 rpm). Growth was clearly evident after three days of incubation, at which time serial transfers were initiated at 48 hr intervals in 15-ml screw-capped culture tubes (0.1 ml inoculum), followed by serial transfers (MOPS omitted) in small pH-controlled fermentation vessels (33 mg dcw l−1inoculum). During the course of this work, supplementing with betaine was discovered to be beneficial for xylose fermentation by KO11 (Underwood et al. 2004) and was included as a supplement after the initial 10 transfers. With betaine (1 mM), cultures were transferred at 24 hr intervals due to more rapid growth. Cell yield and ethanol production improved steadily throughout this enrichment process, which consisted of 38 transfers. Colonies were isolated from the last transfer. All were sensitive to ampicillin, confirming the absence of vector, resistant to apramycin (confirming interrupted ldhA gene in the recipient), and resistant to kanamycin (present in ethanol cassette). Six clones were tested for performance in small fermentations and all were very similar. Two clones were selected and designated LY158 and LY159. Recombinase was used to remove both antibiotic markers simultaneously. Greater than 99% of the resulting clones from LY158 and LY159 were inhibited by both kanamycin and apramycin. Ten clones from each were pooled and used to inoculate small fermentation vessels for further growth-based selection. After 7 serial transfers at 24-h intervals in NBS-9% xylose medium (1 mM betaine), 12 clones were isolated and tested individually in small fermentations. All were similar and two were chosen, designated LY161 and LY160. A further set of 32 serial transfers (24-h intervals) with LY160 showed continuing improvements in performance. One clone was isolated from the last transfer and designated LY160im. A gene library was constructed in pUC18 using EcoRI-digested DNA from strain LY160im and screened for red colonies on aldehyde indicator plates to identify a fragment containing the integrated During the course of selections on xylose-NBS mineral salts media and construction of LY160 and LY161, cellobiose utilization ability declined although the Both lacA and lacY were amplified separately by PCR using the primers shown in Table 2, and using KO11 DNA as a template and cloned into pCR2.1-TOPO. Plasmid pLOI3924 was constructed in three consecutive steps: 1) ligating the cloned lacA fragment (BamHI to NotI; 644 bp) into corresponding sites in pLOI3470; 2) ligating lacY (XhoI to Klenow-treated BamHI; 1,292 bp) into XhoI and Klenow-treated Eco0109I sites; and 3) inserting the SmaI fragment (FRT-kan-FRT; 1,228 bp) from pLOI2511 into Klenow-treated BamHI and NdeI (within lacY) sites. The resulting plasmid contains a Pad-flanked lacY-FRT-kan-FRT-lacA cassette (2,984 bp), which was used to replace the casAB genes in LY160im by homologous recombination. After deletion of kan with recombinase, the resulting strain was designated LY163. Previous studies have demonstrated low levels of ethyl acetate in distillate from KO11; this problem that was remedied by functionally integrating the estZ gene encoding a short chain esterase from Sau3A-digested chromosomal DNA from The Methylglyoxal Bypass is a potential source of lactate in As demonstrated in the graphs shown in The source of this lactate was the Methylglyoxal Bypass, as demonstrated by the finding that this problem was remedied by deletion of methylglyoxal synthase (mgsA). In strain LY168, lactate levels were below detection. Ethanol yield based on total xylose added to the fermentation was 0.5 g ethanol g−1xylose, which is near the theoretical maximum. Elimination of methylglyoxal synthase also improved growth and cell yield, and reduced the time required to complete xylose fermentation ( A further set of 29 serial Fleaker transfers (24-h intervals) with LY168 in AM1 medium plus 9% xylose (Martinez et al., 2007), a new medium, was conducted ( When the casAB genes were deleted a portion of the lacY gene was also deleted, eliminating the ability of the strain to ferment lactose. In order to repair the region, the primer pair lacZ-cynX was used (Table 2, above) to clone the A problem was encountered during serial transfers of strain LY168im in Fleakers containing AM1 medium with 9% xylose. The fermentation broth began to accumulate succinate, leading to the thought that the strain was able to repair the point mutation originally made in the frdBC region. The celY gene from The frdB′-frdC′ fragment (948 bp) was cloned from genomic The next step was to move the cat-sacB cassette into the middle of the genes using PCR, giving the chloramphenicol marker. Using pEL04 (Lee et al., 2001; Thomason et al., 2005; Next, a plasmid was needed containing frdA′- A further set of 15 serial Fleaker transfers (24-h intervals) with LY172 in AM1 medium plus 9% xylose was conducted ( It was still desirable to have the Using plasmid pLOI4162 the PacI fragment (modified cat-sacB cassette in pUC19 with PacI sites flanking cassette; 2,960 bp; Using plasmid pLOI3972 the ldhA-casA-casB-ldhA cassette (4,161 bp) was ligated as a Pad fragment into the pLOI3918 PacI site, creating pLOI3975. There is a unique BglII site in pLOI3975 just behind the ribosomal binding site for casA in which A further set of 12 serial Fleaker transfers (24-h intervals) with LY178E in AM1 medium plus 10% xylose was conducted. Serial transfers in Fleakers were conducted for 4 consecutive days, alternating with 3 days of transfers in 10 mL liquid cultures in AM1 medium supplemented with 5% cellobiose to improve selection for stable the casAB genes ( The foregoing studies demonstrate that there are no inherent barriers to rapid and efficient fermentation of xylose by recombinant It was observed that the addition of betaine increased growth and improved performance but was not essential. Betaine is a protective osmolyte that improves growth in the presence of initial high sugar concentrations, reducing the biosynthetic demands for glutamate and trehalose (Underwood et al. 2004; Zhou et al. 2006a and 2006b). The utility of co-production of bacterial endoglucanases in reducing the requirement for commercial cellulases has been previously demonstrated (Wood and Ingram, 1992; Wood, 1997; Wood et al. 1997b). The most effective of these were found to be those from Strains and plasmids used in the studies described herein are listed in Table 3, below. Strains were maintained on Luria agar plates without added sugar. Antibiotics were added for selection as follows: ampicillin, 50 mg/L; apramycin, 50 mg/L; kanamycin, 50 mg/L; tetracycline, 12.5 mg/L; and spectinomycin, 50 mg/L. Ethanol producing strains were maintained on Luria agar plates which also contained 2% glucose and 40 or 600 mg/L chloramphenicol (alternating daily, under argon). Agar plates used in the screening of endoglucanase production also contained 3 g/L low-viscosity carboxymethylcellulose (CMC). CMC plates were stained with Congo red (Wood et al. 1988) after overnight growth at 37° C. Strains containing pLOI3420 were incubated at 30° C., all others were maintained at 37° C. Standard methods known in the art were used for PCR-based gene cloning, plasmid constructions, and genetic analyses. Methods for integration, chromosomal deletions, integration, and the use of removable antibiotic resistance genes have been previously described (Datsenko and Wanner, 2000; Martinez-Morales et al. 1999; Zhou et al. 2003; Causey et al. 2004). The plasmid used for direct integration of the gene celY encoding the endoglucanase CelY from Strains containing two endoglucanase genes from To facilitate the removal of kan from strain BW32, pFT-A (FLP recombinase) was modified by the addition of an apramycin resistance gene, aac. Plasmid pFT-A was linearized by restriction digestion with ClaI, followed by treatment with the Klenow fragment of Seed cultures (150 ml in 250 ml flasks) were grown for 16 h at 35° C. (120 rpm) in the same media used in pH controlled fermentations but contained 50 g/L glucose. Cells were harvested by centrifugation (5000×g, 5 min) and used as inocula to provide an initial concentration of 33 mg/L dry cell weight (OD550 nm=0.1). Fermentation vessels were previously described (Beall et al. 1991) and contained an initial volume of 350 ml. Glucose fermentations contained 90 g/L sugar and were in OUM1 (Wood 2005). SSFs contained 100 g/L Sigmacell 50 in Luria broth and SSCFs contained 45 g/L Sigmacell 50 plus 40 g/L xylose in OUM1. Cultures were incubated at 35° C. (150 rpm). In fermentations with strain BW35 pCPP2006, spectinomycin was added for plasmid maintenance. All other fermentations contained no added antibiotics. Broth of glucose fermentations and SSFs were maintained at pH 5.2 by the automatic addition of 2N KOH. For improved xylose fermentation, SSCFs were maintained at pH 5.8. To compare the fermentation performance of strains expressing recombinant endoglucanase(s), final strains were used in the fermentation of 90 g/L glucose in OUM1. The CelY producing strain BW34 was equivalent to strain BW21 in both growth and ethanol production ( Table 4 shows product formation and carbon balance after 72 h from 90 g/L glucose in OUM1 by budAB, ethanologenic, endoglucanase producing strains of The increased lactate production was retained with BW35 pCPP2006. The production of acetate is common in strains expressing high levels of recombinant protein (Aristidou et al. 1995; Farmer and Liao, 1997). Two commercial cellulase preparations evaluated for their use in combination with CelY (and CelZ). Both Spezyme CE (GENECOR INT, no longer available commercially) and GC220 are standardized based on their activities on carboxymethyl cellulose, and are reported to be blends of hydrolase activities. To eliminate any potential effects by the media, Luria broth was used in evaluating each enzyme blend. The highest ethanol concentrations of 38 g/L ( In contrast to previous work with Sigmacell and Spezyme CE, there was no apparent benefit from CelY (BW34 vs. BW21) or CelZ (BW35 pCPP2006 vs. BW21) in combination with Spezyme CE (Zhou et al. 2001). At lower enzyme loadings, the results clearly indicate that Spezyme GC220 is the superior to Spezyme CE ( Because the commercial enzymes are blends of activities, it is likely that they are periodically reformulated to meet specific customer requirements and thus are not constant over several years. Also consistent with a change in the formulation of Spezyme CE was the relatively poor performance of the previously developed strain P2 (Doran and Ingram, 1993). The previously developed strain SZ22, expressing CelY (Zhou et al. 2001) was also included for comparison. Using either enzyme (at any loading) the amount of cellulose degradation products (sugar) present at the end of fermentation ( In general, the strains lacking genes of the 2,3-butanediol fermentation pathway (budAB) outperformed those which retain those genes. The elimination of budAB also resulted in the reduction of other by-products as well ( The elimination of need for extensive liquid-solid separation can simplify processing of lignocellulose to ethanol (Wright et al. 1988). The same enzymes (Spezyme CE and Spezyme GC220) used in SSF were again evaluated for their use in SSCFs containing 45 g/L Sigmacell and 40 g/L xylose. An enzyme loading of 50 μl/g cellulose was used for each enzyme. To fully evaluate the potential for commercial application, all SSCFs used OUM1 (Wood 2005), only the budAB strains BW21, BW34, and BW35 pCPP2006 were tested. In SSCF it appears that the reduced hydrolysis rates by Spezyme CE are actually beneficial for the rapid and complete use of xylose ( As in SSF, the by-products formed were similar between strains in SSCF ( Table 5 compares ethanol yields from SSF and SSCF (at enzyme loadings of 50 μL/g Sigmacell) by budAB strains. The most significant increases were seen with Spezyme CE where estimated cellulose conversions were >55% higher in SSCF than in SSF alone. Using Spezyme GC220 in SSCF also resulted in increased ethanol yields from cellulose (14 to 19%). With both enzymes, the largest increase was seen in BW34 in either SSF or SSCF. The improved metabolism of cellulose degradation products, in SSCF, was reflected by the low levels of sugar detected at the end of fermentation ( It is evident that the choice of commercial cellulase can have an impact on the extent of cellulose hydrolysis. The inclusion of xylose, or possibly other free sugars, increased the effectiveness of cellulases used in SSCF. This was likely due to increased biocatalyst concentrations, which were better able to maintain sub-inhibitory concentrations of cellobiose and glucose. When increased biocatalyst concentrations were combined with the production of additional endoglucanase activity, cellulose conversion was even greater, even at fermentation conditions less that optimal for fungal cellulase activity. The incremental improvements in ethanol production from cellulose are illustrated in The strains and plasmids used in this study are listed in Table 6, below. KO11-RD1 and BW34 were the original ethanol producing strains, which were resistance to 600 mg l−1 chloramphenicol. The primers used in this study are listed in Table 7, below. During strain construction, cultures were grown aerobically at 30, 37, or 39 C in Luria broth (10 g l−1 Difco tryptone, 5 g l−1 Difco yeast extract and 5 g l−1 NaCl) containing 2% (w/v) glucose or arabinose. Ampicillin (50 mg l−1), apramycin (50 mg l−1), tetracycline (12.5 mg l−1) or kanamycin (50 mg l−1) were added as needed. For fermentative ethanol production, strains were grown without antibiotics at 37 C in either luria broth or AM1 mineral salts medium (Alfredo et al., 2007) with 10% (w/v) xylose. Standard methods were used for genomic DNA extraction (Qiagen), PCR amplification (Stratagene and Invitrogen), transformation, plasmid extraction (Qiagen), and restriction endonuclease digestion (New England Biolabs). The method for deleting chloramphenicol resistance gene (cat) was modified based on two steps of homologous recombination (Thomason et al., 2005), which would leave no antibiotic gene and foreign gene scars after the gene deletion. At the first recombination, a 200 bp DNA fragment, located in the middle of the cat gene, was replaced by a DNA cassette containing a kanamycin resistance gene (Kan) and levansucrase gene (sacB) ( The Kan gene was amplified from pCR2.1-TOPO using primer set Kan-up/Kan-down (Table 7, above), which was then digested with XhoI and AccI and cloned into pLOI4162 (XhoI and AccI) to replace the cat gene and obtain pLOI4292. The Kan-sacB cassette (2899 bp) was obtained by digesting pLOI4292 with PacI followed by T4 treatment, which was used for further ligation. It was thought at the beginning that there was only one cat gene in the chromosome of KO11-RD1 and BW34, and one round of cat gene deletion would eliminate the cat resistance. A 400 bp DNA fragment located in the middle of cat gene ( After deleting the cat gene, the resulting strains were still resistant to high chloramphenicol concentration. It was thought that there would be more than one cat gene copy in the chromosome of the original strains. If using the previous DNA fragment I (cat′-Kan-sacB-cat″), which came from pLOI4659, for the further recombination, it would have the same chance of integrating at a new cat gene site or a deleted cat gene site. In order to make the further cat gene deletion occurred at a new site, a new plasmid was constructed. A 200 bp DNA fragment located in the middle of cat gene was amplified from KO11-RD1 using primer set cat2-upPstI/cat2-downPstI (Table 7), which was digested with PstI and cloned into pBR322 at PstI site to get pLOI4661. This plasmid DNA was diluted 1000 times and used as template for PCR (using primer set cat2-3/cat2-4, outward amplification). The amplified DNA fragment (cat′″-cat″″-TOPO, 4521 bp) was used to ligate with the Kan-sacB cassette (2899 bp) to make plasmid pLOI4662 ( At the first recombination of cat gene deletion, DNA fragment I (cat′-Kan-sacB-cat″) was electroporated to KO11-RD1 or BW34 having the red recombinase expressing plasmid pKD46 (Datsenko and Wanner 2000) or pLOI3420 (Brent et al., 2005), which was then incubated at 30° C. for 2 h out-growth and then spread in LB plates having ampicillin and kanamycin (for KO11-RD1) or apramycin and kanamycin (for BW34). The kanamycin was for selection of correct recombinant, and the ampicillin or apramycin was to keep pKD46 or pLOI3420 for the second step recombination. After incubation at 30° C. for about 18 h, three colonies were picked and used to prepare competent cell, to which DNA fragment II (cat′-cat″) was electroporated. After that, the culture was incubated at 30° C. for 4 h out-growth and then transferred to a 250 ml flask containing 100 ml LB medium (no sodium chloride) and 10% sucrose. The culture was incubated at 30° C. overnight, which was then streaked in LB plates (no sodium chloride) with 6% sucrose and incubated at either 30 or 39° C. for 16 h. Incubation at 30° C. was to keep the red recombinase plasmid for further cat gene deletion. Colonies were picked from the plates and tested for their ampicillin or apramycin, and kanamycin sensitivity. They were also tested for resistance to different chloramphenicol concentration, and PCR amplification using different primer sets. After deleting all the cat genes, the resulting strains also lost the ethanol producing ability. The pdc gene could not be detected by PCR. In order to produce ethanol, the alcohol gene was re-integrated at either the pflB or rrlE site. Plasmids for integrating alcohol gene at Construction of plasmids for integrating alcohol gene at The methods for constructing plasmids for integrating the alcohol gene at Strain RD1-XZ027 was first transformed with pFT-A, which had the flipase gene, and spread on LB Amp plates. Several colonies were picked and inoculated in a 250 ml flask with 10 ml LB medium with ampicillin. After the OD grew up to 0.1, 1 ml chlorotetracycline stock (20 mg/100 ml LB) was added to induce the flipase gene expression. After growing at 30° C. 6 h, the medium was streaked on LBG plates, and incubated at 39° C. for overnight. Colonies were picked and patched on different plates, including LBG, LB Kan, LB Amp and LB cat40. The kan gene was removed the same way in the The ethanol production of all the strains were tested in 50 ml LB medium with 10% xylose in a 125 ml flask at 37° C. and 100 rpm, which had no pH adjust. The final ethanologenic strains were also tested in AM1 medium with 10% either xylose or glucose. The pH was adjusted to be at 7.0 by automatically adding 2N potassium hydroxide. Cell mass was estimated by measuring the optical density at 550 nm (OD550). Ethanol concentration was measured by GC. Organic acids and sugar concentration were measured by HPLC (Underwood et al., 2002). The two-step homologous recombination method was used for cat gene deletion in KO11-RD1. At the second recombination, both 30 C and 39 C temperature points were used when streaking on LB 6% sucrose plates. The 30 C temperature was used for keeping the red recombinase plasmid pKD46, which could be used for further cat gene deletion. Several colonies were picked in both conditions and patched on different plates, including LBG, LB Kan, LB Amp, and LB Cat with different concentrations (40, 100, 200, 400, 600 mg l−1). For those colonies which came from the 30 C condition, they grew slower and were also sensitive to ampicillin. Two colonies were selected, which were named RD1-XZ001 and RD-XZ002. They were both sensitive to cat400, while resistant to cat200 (as shown in Table 8). Colonies, which came from the 39 C condition, grew faster. Two colonies were selected, which were named RD1-XZ003 and RD-XZ004. They were both sensitive to cat600, while resistant to cat400 (Table 8, below). In Table 8, the primer set cat U/D (cat-up/cat-down) should amplify a 635 bp DNA fragment, which was near the whole cat gene (660 bp), in the native cat gene. In this situation, the PCR result was marked as N (native). If the middle part of the cat gene was deleted, a shorter DNA fragment (462 bp) should be amplified. In this situation, the PCR result was marked as D (deleted). The primer set of both cat-1/cat-2 and pflB-2/pflB-5 was used to detect the tandem duplication of pdc-adhB-cat cassette. All the colonies were still resistant to high chloramphenicol concentration, which suggested that there were still other cat gene copies remained in the chromosome. This is reasonable since the original strain KO11-RD1 was optimized for a long time to increase the ethanol productivity by selecting for resistance to increased chloramphenicol concentration. It was thought that both the cat gene and the alcohol gene (pdc-adhB) were duplicated in the chromosome. The cat gene was tested in these four strains by PCR. The primer set cat-up/cat-down should amplify a 635 bp DNA fragment, which was near the whole cat gene (660 bp), in the native cat gene. If the middle part of the cat gene was deleted, a shorter DNA fragment (462 bp) should be amplified. However, in all the four strains, only the 630 bp DNA fragment was amplified, while the short 462 bp fragment was not obtained. It was possibly because the second step recombination didn't happen at the cat′ and cat″ site. Since there are maybe multiple alcohol genes in the chromosome, the second step recombination had great chance to happen at the pdc and adhB site, which is much bigger than the cat gene. That would remove all the DNA fragments between them, including the cat′-Kan-sacB-cat″ cassette, which would result in no amplification of the short 462 bp fragment. The primer set pflB-2/pflB-5 was used to verify the tandem duplication of pdc-adhB-cat cassette. PCR products were obtained in both the original strain KO11-RD1 and RD1-XZ004. The amplified 2.5 kb DNA fragment were sequenced to obtain the sequence information between the duplication. The primer set cat-1/cat-2 was also used to detect the tandem duplication of pdc-adhB-cat cassette. However, there was no DNA fragment amplified. This was maybe because the DNA fragment between primer cat-1 and cat-2 is so big that the current PCR Kit was not efficient enough to get any amplification. All the four strains were tested for ethanol production in a 125 ml flask fermentation with LB and 10% xylose. Strains RD1-XZ001 and RD1-XZ002 grew much slower and lost almost all the ethanol producing ability. The cell growth and ethanol production after 2 days decreased a little in strains RD1-XZ003 and RD1-XZ004, from 40 g/l in the original strain KO11-RD1 to near 30 g/l (Table 8). Strain RD1-XZ004 was selected for further cat gene deletion. It was thought that during the second recombination of the 1st round of cat gene deletion, all the cat′-Kan-sacB-cat″ cassette was removed because there was no short fragment (462 bp) amplified by the primer set cat-up/eat-down. However, it was still possible that the two-crossover recombination happened at the cat′ and cat″ sites since a negative PCR result is always not strong enough. If so, the cat′ and cat″ would be left at the chromosome. For the further cat gene deletion, if still using DNA fragment I (cat′-Kan-sacB-cat″) at the first recombination step, the two-crossover recombination had the same chance to target either at the new untouched cat site, or at the already deleted cat site. In order to avoid the recombination happen at the already deleted cat site, a new DNA fragment III was created ( At the second recombination, both 30 C and 39 C were used when streaking on LB 6% sucrose plates. Several colonies were picked in both conditions and patched on different plates, including LBG, LB Kan, LB Amp, and LB Cat with different concentrations (40, 100, 200, 400, 600 mg l−1). As during the 1st round of cat gene deletion, those colonies, which came from the 30 C condition, grew slower and were still sensitive to ampicillin. Two colonies were selected, which were named RD1-XZ009 and RD-XZ010. They were both sensitive to cat40 (Table 9, shown below). Colonies, which came from the 39 C condition grew faster. Two colonies were selected, which were named RD1-XZ011 and RD-XZ012. They were both sensitive to cat200, while resistant to cat100 (Table 9). In Table 9, The primer set cat U/D (cat-up/cat-down) should amplify a 635 bp DNA fragment, which was near the whole cat gene (660 bp), in the native cat gene. In this situation, the PCR result was marked as N (native). If the middle part of the cat gene was deleted, a shorter DNA fragment (462 bp) should be amplified. In this situation, the PCR result was marked as D (deleted); The primer set cat2 U/D (cat2-up/cat2-down) was used to amplify the middle of the cat gene. For the native cat gene, the amplified PCR product is 200 bp. For those deleted cat, no DNA fragment should be amplified; The primer set pdc up/1 (pdc-up/pdc-1) was used to detect the pdc gene; The primer set cat-up/pdc-1 was used to detect the tandem duplication of pdc-adhB-cat cassette. The cat gene was tested in these four strains by PCR. When using primer set cat-up/cat-down, the native 635 bp DNA fragment was still amplified from RD1-XZ009 and RD1-XZ010, suggesting there was at least one cat gene remained in the chromosome. However, these two strains were all sensitive to cat40. This might be due to a recombination that occurred in the chromosome because of the extended time that the red recombinase pKD46 was kept at 30 C, which might have removed some essential genes for cell growth and antibiotic resistance. Accordingly, only the strains which came from the 39 C incubation condition were used. As during the 1st round of cat gene deletion, for strains RD1-XZ011 and RD1-XZ012, only the native 635 bp DNA fragment was amplified using primer set cat-up/cat-down, while the short 462 bp DNA fragment was not amplified. The primer set cat2-up/cat2-down was also tested, which should amplify a 190 bp DNA fragment in the native cat gene. No DNA fragment should be amplified after one round of cat gene deletion. The 190 bp DNA fragment was amplified from all the four strains. The primer set pdc-up/pdc-1 was used to test the pdc gene, and it was also amplified from all the four strains. The primer set cat-up/pdc-1 was used to verify the tandem duplication of pdc-adhB-cat cassette. PCR product was obtained from the original strain KO11-RD1, from the parental strain RD1-XZ004 and from strain RD1-XZ011. However, it was not amplified from RD1-XZ012. This suggested that in strain RD1-XZ012, at least two neighboring cat genes were removed together at the 2nd round, which resulted in no DNA fragment amplified by primer set cat-up/pdc-1. All the four strains were tested for ethanol production in a 125 ml flask fermentation with LB and 10% xylose. All the strains grew much slower and, unexpected, lost almost all the ethanol producing ability (Table 9), although the pdc gene was still detected. The cat gene was deleted again in strain RD1-XZ012 using the same strategy as in the 2nd round. At the second recombination, only the 39 C temperature point was used when streaking on LB 6% sucrose plates. Several colonies were picked and patched on different plates, including LBG, LB Kan, LB Amp, and LB Cat with different concentrations (40, 100, 200, 400, 600 mg l−1). All the strains were sensitive to kan, amp, and cat40. The cat gene was tested by PCR. When using primer set cat2-up/cat2-down, no DNA fragment was amplified from all the colonies, indicating that no active cat gene was remained in the chromosome (Table 10, shown below). There was also no DNA fragment amplified from all the colonies when using primer set cat-up/pdc-1. When using primer set cat-up/cat-down, the short 462 bp DNA fragment was amplified from some colonies, while no DNA fragment was amplified from other colonies (Table 10). In Table 10, the primer set cat U/D (cat-up/cat-down) should amplify a 635 bp DNA fragment, which was near the whole cat gene (660 bp), in the native cat gene. In this situation, the PCR result was marked as N (native). If the middle part of the cat gene was deleted, a shorter DNA fragment (462 bp) should be amplified. In this situation, the PCR result was marked as D (deleted); The primer set cat2 U/D (cat2-up/cat2-down) was used to amplify the middle of the cat gene. For the native cat gene, the amplified PCR product is 200 bp. For those deleted cat, no DNA fragment should be amplified; The primer set pdc up/1 (pdc-up/pdc-1) was used to detect the pdc gene. Two colonies were picked from each type and tested by primer set pdc-up/pdc-1. For RD1-XZ016 and RD1-XZ017, the pdc gene fragment was amplified. However, for RD1-XZ018 and RD1-XZ019, no DNA fragment was amplified. It was thought that, for RD1-XZ018 and RD1-XZ019, during the second step recombination, the two-crossover recombination didn't happen at the cat′ and cat″ site while at site outside of the pdc-adhB-cat cassette, which removed all the DNA fragments inside. All the four strains were tested for ethanol production in a 125 ml flask fermentation with LB and 10% xylose. All the strains grew slowly. Strain RD1-XZ016 and RD1-XZ017 produced very few ethanol (below 1 g/l), although the pdc gene was still detected. Strain RD1-XZ018 and RD1-XZ019 produced no ethanol (Table 10). Re-Integration of the Alcohol Gene into RD1-XZ018 In order to obtain the ethanol producing ability, the alcohol cassette (pdc-adhA-adhB) was re-integrated into strain RD1-XZ018. Both the pflB and rrlE genes were chosen as the integration sites. After electroporating the pflB′-pdc-adhA-adhB-FRT-kan-FRT-pflB″ cassette ( The eight strains were tested for ethanol production in a 125 ml flask fermentation with LB and 10% xylose. RD1-XZ024 and RD1-XZ025, which had thin and flat colonies, grew much slower than others and produced very few ethanol. The other strains having thick and raised colonies grew even faster than the original strain KO11-RD1. They also produced near the same amount of ethanol as KO11-RD1, about 40 g/l after 48 h (Table 11, shown below). RD1-XZ027 produced the most ethanol after 24 h (34.6 g/l), suggesting that it had the biggest ethanol productivity. This strain was used for further kan gene removal by the flipase treatment. After removing the kan gene from RD1-XZ027 by the flipaset treatment, four colonies were picked and named RD1-XZ028, RD1-XZ029, RD1-XZ030 and RD1-XZ031. They were tested for ethanol production in a 125 ml flask fermentation with LB and 10% xylose. Cell growth and ethanol production was similar in these four strains. RD1-XZ028 produced the most ethanol (43.6 g/l after 48 h), which was a little higher than the original strain KO11-RD1. The whole process for cat gene deletion in KO11-RD1 and alcohol gene re-integration is summarized in Table 16. The cat gene was also deleted in In Table 12, The primer set cat U/D (cat-up/cat-down) should amplify a 635 bp DNA fragment, which was near the whole cat gene (660 bp), in the native cat gene. In this situation, the PCR result was marked as N (native). If the middle part of the cat gene was deleted, a shorter DNA fragment (462 bp) should be amplified. The primer set of cat-1/cat-2 was used to detect the tandem duplication of cat gene. The cat gene was tested in all six strains by PCR. The primer set cat-1/cat-2 was used to detect the duplication of cat gene. A DNA fragment near 1.8 kb was amplified from the original strain BW34, suggesting that the tandem duplication didn't happen for the whole K.pflB′-pdc-adhB-cat-K.pflB″ cassette, as in KO11-RD1. In contrast, only the cat gene was duplicated. The amplified 1.8 kb DNA fragment was sent for sequencing to obtain the sequence information between the duplication. After the cat gene deletion, the 1.8 kb DNA fragment could only be amplified from strain BW34-XZ105. It was not amplified from all the other 5 strains, suggesting that both cat genes were deleted together. When using the primer set cat-up/cat-down, the 635 bp DNA fragment (Native) was amplified in all the strains except BW34-XZ106. The reason why the short 462 bp fragment was not obtained was thought to be the same as in KO11-RD1. Since it was demonstrated that two cat genes were deleted together due to the cat-1/cat-2 PCR results, it was thought that there were at least three cat gene copies in the chromosome of BW34. It was surprising that no DNA fragment was amplified from BW34-XZ106, and this strain was sensitive to cat40. This was possibly because the two-crossover recombinations of the second step happened outside of the all the cat genes, which resulted in removal of the genes together. All the six strains were tested for ethanol production in a 125 ml flask fermentation with LB and 10% xylose. The cell growth and ethanol production of BW34-XZ105 was similar as the original strain BW34. However, all the other 5 strains grew very slowly, and lost all the ethanol producing ability (Table 7). Re-Integration of the Alcohol Gene into BW34-XZ106 at pflB Site In order to obtain the ethanol production ability, the alcohol cassette (pdc-adhA-adhB) was re-integrated into strain BW34-XZ106. Both the pflB and rrlE genes were chosen as the integration sites. After electroporating the K.pflB′-pdc-adhA-adhB-FRT-kan-FRT-K.pflB″ cassette ( The primer set K.focA-up/pdc-1 was used to verify the recombination. The forward primer (K.focA-up) was upstream of the pflB gene in the chromosome. For strain BW34-XZ109 and BW34-XZ110, it could amplify a product near 1.5 kb. However, for BW34-XZ107 and BW34-XZ108, no DNA fragment was amplified. It was thought that the native pflB 3′-end was deleted during previous cat gene deletion in strain BW34-XZ106. For BW34-XZ109 and BW34-XZ110, the two-crossover recombination happened in the native pflB 5′-end site in the All the four strains were tested for ethanol production in a 125 ml flask fermentation with LB and 10% xylose. The ethanol production after 48 h in BW34-XZ109 and BW34-XZ110 was a little higher than in BW34-XZ107 and BW34-XZ108, all of which were better than the original strain BW34 (Table 13, shown below). Since BW34-XZ110 produced the most ethanol (22.4 g/l after 48 h), it was used for further kan gene removal. In Table 13, The primer set pdc-up/pdc-1 was used to check the pdc gene; The primer set K.focA-up/pdc-1 was used to verify the two-crossover recombination site. After removing the kan gene from BW34-XZ110 by the flipaset treatment, four colonies were picked and named BW34-XZ113, BW34-XZ114, BW34-XZ115, and BW34-XZ116. They were also tested for ethanol production in a 125 ml flask fermentation with LB and 10% xylose. Cell growth and ethanol production was similar in these four strains. BW34-XZ113 produced the most ethanol (22.2 after 48 h). This strain was also tested for ethanol production in AM1 medium with either 10% glucose or 10% xylose. The ethanol production after 48 h in the xylose fermentation (36.4 g/l) was much higher than in glucose (28.7 g/l), both of which were better than in LB medium (22.2 g/l) (Table 14, shown below). There were also some other co-products formed, such as lactate, succinate and acetate (Table 14). Especially in the glucose fermentation, there was 294 mM lactate produced. These co-products were due to the activity of other fermentative enzyme (lactate dehydrogenase, fumarate reductase and acetate kinase) competing with the pyruvate decarboxylase for pyruvate. After electroporating the K.rrlE′-pdc-adhA-adhB-FRT-kan-FRT-K.rrlE″ cassette ( All the four strains were tested for ethanol production in a 125 ml flask fermentation with LB and 10% xylose. The ethanol production after 48 h in BW34-XZ117 and BW34-XZ118 was similar as in BW34-XZ110, which had the alcohol gene integrated at pflB site. In contrast, the ethanol production was much lower in BW34-XZ119 and BW34-XZ120 (Table 15, shown below). BW34-XZ118 was used for further kan gene removal since it produced the most ethanol (22.5 g/l after 48 h). After removing the kan gene from BW34-XZ118 by the flipaset treatment, four colonies were picked and named BW34-XZ121, BW34-XZ122, BW34-XZ123, and BW34-XZ124. They were also tested for ethanol production in a 125 ml flask fermentation with LB and 10% xylose. Cell growth and ethanol production was similar in these four strains. BW34-XZ123 produced the most ethanol (23.2 g/l after 48 h), which was a little higher than in BW34-XZ113 (22.2 g/l), which had the alcohol gene integrated at pflB site. Table 16, shown below shows a summary of cat gene deletion in KO11-RD1 and re-integration of alcohol gene and Table 17, shown below shows a summary of cat gene deletion in BW34 and re-integration of alcohol gene. In summary, several strains of These reengineered strains were tested using standard procedures for simultaneous saccharification and fermentation (SSF) reactions with acid hydrolyzed bagasse fiber. Table 19, below, shows a compositional analysis of belt cakes used in these studies. SSF of strains XZ112, 113, 115 was performed using VOP #12-SSF of Bagasse with the following exception: 100 g dry wt bagasse was placed into the fermentation vessel with 600 mL of tap water, and was autoclaved for 30 minutes at 121° C. Due to limited substrate, SSF of strains XZ112 and XZ113 were performed on Screw Press bagasse “SP5C_C2”, and SSF of strain XZ115 was performed on Cake #070207T150-BW-CAKE-ROLL. SP5C_C2 (pH 6.46) was not additionally washed as previous BW34 fermentations reached 72% conversion in 72 hours. Cake #070207T150-BW-CAKE-ROLL was washed to pH 4.96 using VOP #28-Biomass Fiber Washing. As shown in Table 20, below, provides a summary of recent literature for ethanol production from xylose by recombinant biocatalysts. Many of these are known to require complex nutrients. Whether compared in complex medium or mineral salts medium, none ferment xylose to ethanol with a higher yield or titer than the novel recombinant strains of All patents, published patent applications and other references disclosed herein are hereby expressly incorporated herein in their entireties by reference. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.RELATED APPLICATIONS
GOVERNMENT SPONSORED RESEARCH
BACKGROUND OF THE INVENTION
SUMMARY OF THE INVENTION
BRIEF DESCRIPTION OF THE DRAWINGS
DETAILED DESCRIPTION OF THE INVENTION
I. DEFINITIONS
II. RECOMBINANT CELLS
III. METHODS OF MAKING
IV. METHODS OF USE
Methods for Producing Ethanol
EXEMPLIFICATION
Materials and Methods:
Strains/ plasmids Relevant Genotype Source or Citation DH5α lacZ Δ M15 recA Invitrogen S17-1λpir thi pro recA hsdR RP4-2-tet::Mu aphA::Tn7λpir, spc tet de Lorenzo et al. 1990 TOP10F′ F′ {lacIqTn10 tet)} Invitrogen W Prototroph ATCC 9637 NC3 B/r hsdR phn Wanner et al. 1977 KO11 W Δfrd pfl+ pfl::pdcZmadhBZmcat Ohta et al. 1991 SZ110 W ΔadhE ΔackA Δpfl celYEccasAcasBKo Zhou et al. 2005 LY149 SZ110 ΔldhA::FRT This study LY151 LY149 pfl+(pflA-FRT-aac-FRT-ycaK), AacR This study LY158 LY151 pdcZm-adhAZm-adhBZm-FRT-kan-FRT, This study pfl+ (pflA-FRT-aac-FRT-ycaK), AacR, KanR LY159 LY151 pdcZm-adhAZm-adhBZm-FRT-kan-FRT, pfl+ (pflA-FRT- This study aac-FRT-ycaK), AacR, KanR LY160 LY158/159 rrlE′-pdcZm-adhAZm-adhBZm-FRT-rrlE′, This study pfl+ (pflA-FRT-ycaK) LY160im LY160 rrlE′-pdcZm-adhAZm-adhBZm-FRT-rrlE′, This study pfl+ (pflA-FRT-ycaK) LY161 LY158/159 rrlE′-pdcZm-adhAZm-adhBZm-FRT-rrlE′, This study pfl+ (pflA-FRT-ycaK) LY163 LY160 lac′Y-FRT-lacA (ΔcasAcasBKo) This study LY165A LY163 adhE′::Zm frg-estZPp-FRT::adhE′ This study LY165C LY163 adhE′::Zm frg-estZPp-FRT::adhE′ This study LY168 LY165C ΔmgsA::FRT This study LY168im LY168 ΔmgsA::FRT This study LY169 LY168im lacY-lacA+ This study LY170 LY169 frdB′-cat-sacB-frdC′ This study LY172 LY170 frdA′-Zm frg-celY-frdC′ ΔfrdB This study LY172im LY172 frdA′-Zm frg-celY-frdC′ ΔfrdB This study LY173 LY172im ldhA′-cat-sacB-casAKo-casBKo-ldhA′, CamR This study LY178A, C, D LY173 ldhA′-Zm frg-casAcasBKo-ldhA′ This study E&F LY180 LY178E ldhA′-Zm frg-casAcasBKo-ldhA′ This study LY186 LY180 ldhA′-Zm frg-casAcasBKo-ldhA′ This study plasmids pCCD5-lacZ ColE1, rrnBT1 terminator, bla Cebolla et al. 2002 pCR2.1- ColE1, TOPO T/A cloning vector, bla kan Invitrogen TOPO pKD46 pSC101ts, repA101 γβ exo, (Red recombinase), bla Datsenko & Wanner 2000 pFT-A pSC101ts, flp (FLP recombinase), bla Posfai et al. 1997 pBluescript II ColE1, bla Stratagene SK+ pLOI2228 pSC101ts, two FRT sites in MCS, cat Martinez-Morales et al. 1999 pLOI2511 ColE1, with FRT sites flanking the kan, bla Purvis et al. 2005 pLOI3421 ColE1, with FRT sites flanking the aac gene, bla aac Wood et al. 2005 pLOI3469 R6K, oriT, PacI site within the Tn5 I and O ends, tnp, bla Purvis et al. 2005 pLOI3470 pBluescript II SK+, SacI(blunt)-PacI linker, This study KpnI(blunt)-PacI linker, pCCD5-laZ EcoRI-NotI (blunt) PCR product rrnBT1 terminator into EcoRI-SmaI, ColE1, bla pLOI3472 pLOI3470, pLOI2511EcoRI-SmaI FRT-kan-FRT in BstXI, This study ColE1, bla kan pLOI3495 pLOI3470, pLOI3421 EcoRI-SmaI FRT-aac-FRT in This study BamHI, PacI flanked FRT-aac-FRT, bla, aac pLOI3918 pLOI2228, ClaI-HindIII deletion with PacI linker and FRT This study site deletion, pSC101ts, cat pUC18 ColE1, bla New England Biolabs pEL04 ColE1, cat-sacB, CamR Lee et al. 2001 ldhA pLOI3497 SmaI/EcoRI FRT-aac-FRT from pLOI3421 in MfeI/SalI of This study ldhA, ldhA′-FRT-aac-FRT-ldhA′ bla, kan, aac pfl pLOI3901 ycaO-focA-pflB-pflA-FRT-aac-FRT-trm-ycaK-ycaN′, ColE1, This study bla aac pdc, adhA, adhB pLOI135 Keshav et al. 1990 pLOI295 Ingram et al. 1987 pLOI3491 pdc-adhA-adhB-FRT-kan-FRT, R6K, oriT, tnp, bla kan This study Integration of ethanol genes site pLOI3951 LY160 EcoRI genomic fragment, ColE1, bla This study deletion of casAB pLOI392 lacY-FRT-kan-FRT-lacY, ColE1, kan bla estZ pAH181 Hasona et al. 2002 pLOI3920 adhE′-estZ-FRT-aac-FR-:adhE′, pSC101ts, cat aac This study pLOI3925A adhE- This study aac pLOI3925C adhE′- This study cat aac mgsA pLOI3940 mgsA′-FRT-aac-FRT-mgsA′, ColE1, bla kan aac This study frd region pLOI3958 frdB′-frdC′, ColE1, bla This study pLOI3959 frdB′-cat-sacB-frdC′, ColE1, bla cat This study pLOI3961 frdA′-Zm frg-celY-frdC′, ColE1, bla This study ldhA-casAB pLOI4162 cat-sacB flanked by PacI sites, ColE1, bla This study pLOI1910 casAB, ColE1, bla Moniruzzaman et al., xxx pLOI3971 ldhA, ColE1, bla This study pLOI3972 PCR of casAB from pLOI1910, ldhA′-casABKO-ldhA′, This study ColE1, bla pLOI3973 ldhA′-cat-sacB-casA-casB-ldhA′, ColE1, bla This study pLOI3975 ldhA-casA-casB-ldhA, pSC101ts, cat This study pLOI3976A-K ldhA′-Zm frg-casA-casB-ldhA, pSC101ts, cat This study Primers Primer Sequence ldhA N-terminus 5′-TTGCTCTTCCATGAAACTCGCCGTTTATAGCACA-3′ (SEQ ID NO: 1) C-terminus 5′-TTGCTCTTCGTTAAACCAGTTCGTTCGGGCAGG-3′ (SEQ ID NO: 2) lacA N-terminus 5′-TTGCTCTTCCATGCCAATGACCGAAGAATAAGAG-3′ (SEQ ID NO: 3) C-terminus 5′-TTGCTCTTCGTTAAACTGACGATTCAACTTTATA-3′ (SEQ ID NO: 4) lacY N-terminus 5′-TTGCTCTTCCATGTACTATTTAAAAAACACAAAC-3′ (SEQ ID NO: 5) C-terminus 5′-TTGCTCTTCGTTAAGCGACTTCATTCACCTGAC-3′ (SEQ ID NO: 6) adhE N-terminus 5′-TTGCTCTTCCATGGCTGTTACTAATGTCGCTGAA-3′ (SEQ ID NO: 7) C-terminus 5′-TTGCTCTTCGTTAAGCGGATTTTTTGCGTTTTTTCT-3′ (SEQ ID NO: 8) mgsA N-terminus 5′-TATTGCGCTGGTGGCACACG-3′ (SEQ ID NO: 9) C-terminus 5′-ACGGTCCGCGAGATAACGCT-3′ (SEQ ID NO: 10) estZ N-terminus 5′-AGATCTTCTGGAGAATCGAACGATGTCCCTG-3′a (SEQ ID NO: 11) C-terminus 5′-GAATTCATCACCGCCAAGTACAGCTT-3′b (SEQ ID NO: 12) adhA N-terminus 5′-ACTAGTGATCGTAATCGGCTGGCAAT-3′c (SEQ ID NO: 13) C-terminus 5′-ACTAGTGTTTATGCTTCCGCCTTCAC-3′c (SEQ ID NO: 14) ycaN-pflB′ N-terminus 5′-GGCGCAATCGTTCATAGAGA-3′ (SEQ ID NO: 15) C-terminus 5′-ATATGGCCGTGGCCGTATCA-3′ (SEQ ID NO: 16) ycaO-pfLA′ N-terminus 5′-AATGACGATGTGCCAGAAGG-3′ (SEQ ID NO: 17) C-terminus 5′-GGTGTCGCGGTTATGACAAT-3′ (SEQ ID NO: 18) rrlE-pdc N-terminus 5′-GGACGGAGAAGGCTATGTTG-3′d (SEQ ID NO: 19) C-terminus 5′-TGCGAAGTGATGCTTGAGAC-3′e (SEQ ID NO: 20) rrnBTI 5′-AAGCGGCCGCAAATTTCCAGGCATCAAATAA-3′a (SEQ ID NO: 21) (termi- 5′-AAGAACGTGGGAATTCCCTGGCAGTTTATGG-3′b (SEQ ID NO: 22) nator) lacZ-cynX N-terminus 5′-GAAGTGACCAGCGAATACCT-3′ C-terminus 5′-GGTGATGCCTTCGGTGATTA-3′ lacY′ N-terminus 5′-TTAAGCTGGCACTGGAACTG-3′ C-terminus 5′-AGCGACTTCATTCACCTGAC-3′ frdB′-frdC′ N-terminus 5′-ACCGCACGGCATAGGGCATT-3′ C-terminus 5′-AGAGCTGCCGCCAGAGTGAT-3′ JMcatsacB N-terminus 5′-TTAGCTAGCATGTGACGGAAG-3′ Nheg C-terminus 5′-CCGCTAGCATCAAAGGGAAAA-3′ NhefrdB-Cg N-terminus 5′-ACGCTAGCGTGTAATCACGCAGGAAGG-3′ C-terminus 5′-ACGCTAGCTTACATGCGCGCGAAGGC-3′ XhofrdA- N-terminus 5′-ACCTCGAGTGCACAGGCTGTTCCAGACC-3′ NhecelYgh C-terminus 5′-ACGCTAGCGCGCGTTGGCCGATTCATTA-3′ BglIIcasA- N-terminus 5′-TGAGATCTTTAAGGAAAAACAGCATGGA-3′ MfeIcasBij C-terminus 5′-GCACAATTGCGCGTAACGGCGTAATACGAA-3′ BglIIldhA- N-terminus 5′-GACAGATCTCGATGGCGTGTTCAGCAACGG-3′ ldhAi C-terminus 5′-CCAGTCGCGGTGCATTGATTGATTCTCAGG-3′ aincludes BglII site;bincludes EcoRI site;cincludes SpeI site;dwithin rrnB;ewithin pdc;fincludes NotI site Example 1
Construction of New Host Strains for
Example 2
Construction of Transposome Containing a Full Set of Ethanol Genes from
Example 3
Integration and Selection of New Ethanologenic
Example 4
Integration Site of Ethanol Genes in
Example 5
Deletion of casAB
Example 6
Addition of Esterase
Example 7
Deletion of mgsA
Example 8
Fermentation of Xylose in Mineral Salts Medium
Example 9
Fermentation in AM1 Medium
Example 10
Repair of the lac Region
Example 11
Deletion of frd Operon and Re-Integration of celY
Example 12
Integrations of casAB Genes from
Example 13
Improved Ethanologenic Recombinant Bacteria
Example 14
Engineering of BW34
lacZΔM15 recA Bathesda Research Labs λ pir Lab Stocks (Z.m pdc.adhB), cat, Er.c. celYcelZ) Zhou et al. 2001 SZ21 ΔcelZ.aac Zhou et al. 2001 This study (Chapter 2) (Z.m pdc.adhB), cat, ΔbudAB This study (Chapter 2) BW21, celY, kan This study SZ21 ΔbudAB, tet This study BW21, celY This study SZ21 ΔbudAB This study pCPP2006 rpm. −40 kbp frag. Containing our genes from He et al. 1991 pFT-A bla, FLP recombinase Posafi et al. 1997 pFT-K kan, FLP recombinase Posafi et al. 1997 pLOI2224 R6K ori, kan, FRT flanked MCS (AscI) Martinez-Morales et al. 1999 pLOI2348 celY from Zhou et al. 2001 pLOI3420 λ Red Recombinase, RepA ori, aac This study pLOI3421 FRT-aac-FRT This study pLOI3290 DraI aac frag. from pLOI3421 in pFT-A ClaI This study pLOI3293 celY, M5a1glgP frag. (AscI) from pLOI2348 in pLOI2224 AscI This study BW21 4 29 ± 21 4 ± 1 13 ± 3 5 ± 1 2 ± 1 926 ± 17 100 ± 2 BW34 4 25 ± 10 7 ± 3 14 ± 1 7 ± 1 2 ± 0 917 ± 32 91 ± 1 BW35 3 94 ± 12 17 ± 8 12 ± 2 0 ± 0 1 ± 1 833 ± 24 100 ± 3 BW35 pCPP2006 3 88 ± 26 18 ± 3 15 ± 1 20 ± 3 0 ± 1 788 ± 46 98 ± 1 SSCF Yield (%)a,b Xylose + SSF Enzyme Strain Cellulose Cellulosec Yield (%)d,c Spezyme CE BW21 81.8 71.2 45.8 BW35 pCPP2006 82.5 72.4 43.6 BW54 86.6 79.8 47.0 Spezyme BW21 75.0 58.9 51.8 GC220 BW35 pCPP2006 75.3 59.5 37.9 BW34 80.9 70.1 58.8 a% of theoretical based on 0.51 g ethanol per g xylose and/or 0.568 g ethanol per g cellulose. bSSCFs were in OUM1 medium, pH 5.8 and yields ignore residual xylose. cAssumes 95% of theoretical ethanol yield (19.4 g/L) from added xylose. dSSFs were in Luria broth, pH 5.2. Example 15
Eliminating Chloramphenicol Resistance in Ethanologenic KO11-RD1 and BW34
Strains, Plasmids, Media and Growth Conditions
Plasmid pCR2.1-TOPO pLOI4162 Bla cat; pLOI4292 Bla kan; Kan amplified from pCR2.1-TOPO, digested with XhoI and AccI, then cloned into pLOI4162 to replace cat gene Cat deletion (1stround) pLOI4657 Bla kan; cat (400 bp fragment, using primer JMcatUP/JMcatDOWN) amplified from KO11-RD1 cloned into pCR2.1-TOPO vector pLOI4658 Bla; pLOI4657 digested with SfoI and self-ligated to inactivate Kan resistance pLOI4659 Bla kan; Kan-sacB cassette from pLOI4292 (PacI, T4) cloned into cat in pLOI4658 pLOI4660 Bla kan; PCR fragment amplified from pLOI4657 (using cat-1/cat-2 primers), kinase treated, and then self-ligation Cat deletion (2ndand 3rdround) pBR322 Bla tet; pLOI4661 Tet; cat (200 bp fragment, using primer cat2-upPstI/cat2-downPstI) amplified from KO11-RD1, digested with PstI and cloned into pBR322 at PstI site pLOI4662 Bla kan; Kan-sacB cassette from pLOI4292 (PacI, T4) cloned into cat in pLOI4661 pdc-adhA-adhB integrated in pLOI2225 cat, R6K pLOI2394 bla; deletion of multiple cloning site (KpnI-HindIII) in pLOI2302 pLOI3491 bla kan; pdc-adhA-adhB-FRT-Kan-FRT pLOI4664 Bla; pflB amplified from digested with EcoRI and cloned into pLOI2394 at EcoRI site pLO14665 Bla kan; pdc-adhA-adhB-FRT-Kan-FRT cassette from pLOI3491 (PacI, blunted by T4 DNA polymerase) cloned into pflB in pLOI4664 pLOI4666 Kan cat; pflB′-pdc-adhA-adhB-FRT-Kan-FRT-pflB″ cassette from pLOI4664 (AscI fragment) cloned into AscI site of pLOI2225 pLOI4670 Bla; rrlE amplified from digested with EcoRI and cloned into pLOI2394 at EcoRI site pLOI4671 Bla kan; pdc-adhA-adhB-FRT-Kan-FRT cassette from pLOI3491 (PacI, blunted by T4 DNA polymerase) cloned into rrlE in pLOI4670 pLOI4672 Kan cat; rrlE′-pdc-adhA-adhB-FRT-Kan-FRT-rrlE″ cassette from pLOI4671 (AscI fragment) cloned into AscI site of pLOI2225 pdc-adhA-adhB integrated in pLOI4637 bla kan; pflB (PCR) from pLOI4645 bla; pflB gene from pLOI4637 (KpnI-XbaI, blunted by T4 DNA polymerase) cloned into pLOI2394 at EcoRI site (blunted by Klenow) pLOI4646 bla kan; pdc-adhA-adhB-FRT-Kan-FRT cassette from pLOI3491 (PacI, blunted by T4 DNA polymerase) cloned into pflB in pLOI4645 pLOI4649 kan cat; K.pflB′-pdc-adhA-adhB-FRT-Kan-FRT-K.pflB″ cassette from pLOI4646 (AscI fragment) cloned into AscI site of pLOI2225 pLOI4673 Bla; rrlE amplified from K.pflB-down-EcoRI), digested with EcoRI and cloned into pLOI2394 at EcoRI site pLOI4674 Bla kan: pdc-adhA-adhB-FRT-Kan-FRT cassette from pLOI3491 (PacI, blunted by T4 DNA polymerase) cloned into K.rrlE in pLOI4673 pLOI4675 Kan cat; K.rrlE′-pdc-adhA-adhB-FRT-Kan-FRT-K.rrlE″ cassette from pLOI4674 (AscI fragment) cloned into AscI site of pLOI2225 Primers Kan-up AGCTCGAG AGACTGGGCGGTTTTATGG Kan-down AGGTATAC GCGACACGGAAATGTTGAAT Cat deletion JMcatUP ACGGT GAGCT GGTGA TATGG JMcatDOWN GCATT CTGCC GACAT GGAAG Cat-1 TATACGCAAGGCGACAAGGT Cat-2 TCGTCGTGGTATTCACTCCA Cat2-upPstI atcctgcagTTTCCGGCAGTTTCTACACA Cat2-downPstI atcctgcagTTTGCCCATGGTGAAAACG Cat2-3 CAATCCCTGGGTGAGTTTCA Cat2-4 GGGAAATAGGCCAGGTTTTC Cat2-up TTTCCGGCAGTTTCTACACA Cat2-down TTTGCCCATGGTGAAAACG pdc-adhA-adhB integrated in pflB-up-EcoRI gcagaattcCCTGGCAAACCTGATGGTAT pflB-down-EcoRI gcagaattcACTCAGCTTGCAGGATTGCT pflB-up CCTGGCAAACCTGATGGTAT pflB-down ACTCAGCTTGCAGGATTGCT pflB-1 CGTACAATAAAGGCTCCACGA pflB-2 CACCTACCTTCTTAAGTGGATTTTT pflB-up2 TGTCCGAGCTTAATGAAAAGTT pflB-down2 CGAGTAATAACGTCCTGCTGCT pflB-3 GGTTACTTCCACCACGAAGC pflB-4 GTGAGTGCGGTTTTCCAGTT pflB-5 AAACGGGTAACACCCCAGAC pflB-6 CGGAGTGTAAACGTCGAACA pdc-adhA-adhB integrated in rrlE-up-EcoRI gcagaattcAGCCAGGATGTTGGCTTAGA rrlE-down-EcoRI gcagaattcAAAGGTTCACGGGGTCTTTC rrlE-up AGCCAGGATGTTGGCTTAGA rrlE-down AAAGGTTCACGGGGTCTTTC rrlE-1 AGCAACAAATGCCCTGCTT rrlE-2 CACCGTAGTGCCTCGTCAT pdc-adhA-adhB integrated in pflB-up2 M5A1 GCCGTAGCCTGATGGATAAA pflB-down2 M5A1 ACGTCCTGCTGCTGTTCTTT pflB-2 M5A1 ACTCAGTCCGAGCTGACCAT pflB-3 M5A1 TCACCTTTCGCAAAACCTTC pdc-adhA-adhR integrated in K.rrlE-up-EcoRI gcagaattcTTAAGTGGGAAACGATGTGG K.rrlE-down-EcoRI gcagaattcAAAGGTTCACGGGGTCTTTC K.rrlE-up TTAAGTGGGAAACGATGTGG K.rrlE-down AAAGGTTCACGGGGTCTTTC K.rrlE-1 GAAGTGACAAATGCCCTGCT K.rrlE-2 CACCGTAGTGCCTCGTCAT Genetic Methods
Plasmid Construction for Cat Gene Deletion (1st Round)
Plasmid Construction for Cat Gene Deletion (2nd and 3rd Round)
Cat Gene Deletion
Re-Integration of Alcohol Gene
Removal of Kan Gene by Flipase
Fermentation
Analysis
The 1st Round of Cat Gene Deletion in KO11-RD1
PCR Cat Cat Cat PflB OD550 EtOH (g/L) Strains Resistance 1/2 U/D 5/2 D1 D2 D1 D2 KO11- 600R − N + 14.2 18 28.2 40.8 RD1 RD1- 400S − N N/A 3.8 3.7 2.3 1.8 XZ001 200R RD1- 400S − N N/A 5.6 7.0 4.2 8 XZ002 200R RD1- 600S − N N/A 12 12 12.2 30.1 XZ003 400R RD1- 600S − N + 11.2 12.4 12.1 30.2 XZ004 400R The 2nd Round of Cat Gene Deletion in RD1-XZ004
Cat PCRa Re- Cat- sist- Cat Cat2 Pdc up OD550 EtOH (g/L) Strains ance U/D U/D Up/1 Pdc-1 D1 D2 D1 D2 KO11- 600R N + + + 14.2 18 28.2 40.8 RD1 RD1- 600S N + + + 11.2 12.4 12.1 30.2 XZ004 400R RD1- 40S N + + − 3.2 3.2 0.7 0.5 XZ009 RD1- 40S N + + − 3.3 3.3 0.8 0.5 XZ010 RD1- 100R N + + + 4.0 4.1 2.6 2.1 XZ011 200S RD1- 100R N + + − 3.2 3.2 0.8 0.5 XZ012 200S The 3rd Round of Cat Gene Deletion in RD1-XZ012
Cat PCRa Re- Cat- sist- Cat Cat2 Pdc U OD550 EtOH (g/L) Strains ance U/D U/D Up/1 Pdc-1 D1 D2 D1 D2 KO11- 600R N + + + 14.2 18 28.2 40.8 RD1 RD1- 600S N + + + 11.2 12.4 12.1 30.2 XZ004 400R RD1- 100R N + + − 3.2 3.2 0.8 0.5 XZ012 200S RD1- 40S D − + − 2.8 2.6 0.9 0.6 XZ016 RD1- 40S D − + − 2.9 2.7 0.8 0.5 XZ017 RD1- 40S − − − − 2.4 2.3 0 0 XZ018 RD1- 40S − − − − 2.4 2.4 0 0 XZ019 Colony OD550 EtOH (g/L) Strains physiology D1 D2 D1 D2 KO11- 14.2 18 28.2 40.8 RD1 RD1-XZ018 2.4 2.3 0 0 RD1-XZ020 Thick and 18 16 30.4 41.5 raised RD1-XZ021 Thick and 17.5 14 32.4 42.4 raised RD1-XZ022 Thick and 18.4 17 33.3 40.4 raised RD1-XZ023 Thick and 19 18.5 33.2 40.8 raised RD1-XZ024 Thin and 2.8 2.6 0.6 0.5 flat RD1-XZ025 Thin and 2.7 2.6 0.3 0.2 flat RD1-XZ026 Thick and 18 18 32.8 39.2 raised RD1-XZ027 Thick and 18 18.8 34.6 38.4 raised RD1-XZ028 17.2 16.2 33.8 43.6 RD1-XZ029 17.6 17.2 33.7 41.3 RD1-XZ030 17.4 17 32.6 41.3 RD1-XZ031 17 16.2 33.3 40.8 Cat Gene Deletion in BW34
PCRa Cat Cat Cat OD550 EtOH (g/L) Strains Resistance 1/2 U/D D1 D2 D1 D2 BW34 600R + N 8.2 7.6 11.2 18.4 BW34- 400S − N 1.7 2.2 0.2 0 XZ101 200R BW34- 400S − N 2.0 2.1 0.2 0 XZ102 200R BW34- 400S − N 2.1 2.2 0.2 0.2 XZ103 200R BW34- 400S − N 2.1 2.3 0.2 0 XZ104 200R BW34- 600R + N 6.8 7.0 7.5 12.3 XZ105 BW34- 40S − − 2.3 1.8 0.2 0 XZ106 PCRa Colony pdc pflB focA/ OD550 EtOH (g/L) Strains Physiology up/1 U/D pdc 1 D1 D2 D1 D2 BW34 − + − 8.2 7.6 11.2 18.4 BW34- − + − 2.3 1.8 0.2 0 XZ106 BW34- Thin and flat + + − 8.0 7.6 9.7 19.9 XZ107 BW34- Thin and flat + + − 7.5 7.6 9.6 19.4 XZ108 BW34- Thick and + − + 8.0 6.6 12.7 20.9 XZ109 dense BW34- Thick and + − + 9.5 7.4 12.8 22.4 XZ110 dense BW34- 7.3 9.5 12.6 22.2 XZ113 BW34- 7.4 9.8 13 22.1 XZ114 BW34- 7.7 7.0 13 21.9 XZ115 BW34- 7.3 7.6 13.1 21.2 XZ116 LB 10% xylose 9.5 22.2 no pH control AM1 10% 8.2 36.4 63.7 63.1 26.8 Xylose (initial OD 0.1) AM1 10% 4.6 28.7 294 19.3 16.1 Glucose (initial OD 0.1)
Re-Integration of the Alcohol Gene into BW34-XZ106 at rrlE Site
Colony OD550 EtOH (g/L) Strains Physiology D1 D2 D1 D2 BW34 8.2 7.6 11.2 18.4 BW34- 2.3 1.8 0.2 0 XZ106 BW34- Thick and 6.2 5.4 13 22 XZ117 raised BW34- Thick and 6.9 6.4 14.1 22.5 XZ118 raised BW34- Thin and flat 5.9 5 7 11.7 XZ119 BW34- Thin and flat 7.2 5.6 10.1 13.5 XZ120 BW34- 7.0 5.5 13.7 22.5 XZ121 BW34- 7.1 4.8 13.2 22.5 XZ122 BW34- 7.5 5.8 14.1 23.2 XZ123 BW34- 6.9 5.0 13.7 22.2 XZ124 Cat OD550 EtOH (g/L) Step Process Strains Resistance D1 D2 D1 D2 0 KO11-RD1 600R 14.2 18 28.2 40.8 1 1stround of cat RD1-XZ004 600S 11.2 12.4 12.1 30.2 deletion 400R 2 2ndround of cat RD1-XZ012 100R 3.2 3.2 0.8 0.5 deletion 200S 3 3rdround of cat RD1-XZ018 40S 2.4 2.3 0 0 deletion 4 Alcohol gene RD1-XZ027 40S 18 18.8 34.6 38.4 re-integrated at rrlE site 5 Removal of kan RD1-XZ028 40S 17.2 16.2 33.8 43.6 gene Cat OD550 EtOH (g/L) Step Process Strains Resistance D1 D2 D1 D2 0 BW34 600R 8.2 7.6 11.2 18.4 1 Cat deletion BW34- 40S 2.3 1.8 0.2 0 XZ106 2A Alcohol gene BW34- 40S 9.5 7.4 12.8 22.4 re-integrated XZ110 at pflB site 2B Removal of BW34- 40S 7.3 9.5 12.6 22.2 kan gene XZ113 3A Alcohol gene BW34- 40S 6.9 6.4 14.1 22.5 re-integrated XZ118 at rrlE site 3B Removal of BW34- 40S 7.5 5.8 14.1 23.2 kan gene XZ123 BW34-XZ106 Cat deletion in BW34 M5A1, ΔbudAB::FRT BW34-XZ107 Re-integrating the alcohol Thin and flat M5A1, ΔbudAB::FRT, BW34-XZ108 gene into BW34-XZ106 pflB′-pdc-adhA-adhB-FRT- BW34-XZ109 at pflB site Thick and Kan-FKT-pflB″ BW34-XZ110 raised BW34-XZ111 Removing Kan from M5A1, ΔbudAB::FRT, BW34-XZ112 BW34-XZ108 pflB′-pdc-adhA-adhB:FRT- BW34-XZ113 Removing Kan from pflB″ BW34-XZ114 BW34-XZ110 BW34-XZ115 BW34-XZ116 BW34-XZ117 Re-integrating the alcohol Thick and M5A1, ΔbudAB::FRT, BW34-XZ118 gene into BW34-XZ106 raised rrlE′-pdc-adhA-adhB-FRT- BW34-XZ119 at rrlE site Thin and flat Kan-FRT-rrlE″ BW34-XZ120 BW34-XZ121 Removing Kan from M5A1, ΔbudAB::FRT, BW34-XZ122 BW34-XZ118 rrlE′-pdc-adhA-adhB:FRT- BW34-XZ123 rrlE″ BW34-XZ124 SP5C_C2 55.6% Glucan 3.75% Xylan 070207T150-BW-CAKE 53.44% Glucan Xylan ND Ethanol Production from Xylose by Recombinant Organisms Xylose Ethanol Yield Strain (g L−1) Nutrients (g L−1) (g g−1) Reference Mineral medium 2.8 0.03 90 LB 9.1 0.1 As used in this study (ATCC 11303) Ec KO11 90 LB 43.2 0.48 This study Ec LY168 90 LB 45.3 0.50 This study Ec KO11 90 Min 26.9 0.30 This study Ec LY165 90 Min 44.9 0.50 This study Ec LY168 90 Min 45.5 0.51 This study Ec FBR5(pLOI297) 95 LB 41.5 0.44 Dien et al. 2000 Ko M5A1(pLOI555) 100 LB 46.0 0.46 Ohta et al. 1991 Zm CP4(pZB5) 25 YE 11.0 0.44 Zhang et al. 1995 Zm CP4(pZB5) 60 YE 23.0 0.38 Lawford & Rousseau 1999 Zm CP4(pZB5) 80 + 8 G YE 36.6 0.42 Lawford & Rousseau 1999 Zm ZM4/Ac(pZB5) 60 LB 11.0 0.44 Jeon et al. 2005 Ssp 1400(pLNH32) 50 YEP 23.0 0.46 Ho et al. 1998 Sc RE700A(pKDR) 50 YEP 23.0 0.46 Sedlak & Ho 2004 Sc RWB202-AFX 20 Synth. 8.6 0.43 Kuyper et al. 2004 Sc RWB217 20 Synth. 8.7 0.44 Kuyper et al. 2005 Abbreviations: LB, yeast extract + tryptone; Min, minerals + 1 mM betaine; YE, yeast extract supplemented with phosphate; YEP, supplemented with yeast extract and peptone; Synth, minerals supplemented with a mixture of vitamins; 8 G, 8 g of glucose added per liter. REFERENCES
INCORPORATION BY REFERENCE
EQUIVALENTS